Open Research Online



The Open University's repository of research publications and other research outputs

GABA Modulates Frequency-Dependent Plasticity in Humans

Journal Item

How to cite:

Lea-Carnall, C. A.; Williams, S. R.; Sanaei-Nezhad, F.; Trujillo-Barreto, N. J.; Montemurro, M. A.; El-Deredy, W. and Parkes, L. M. (2020). GABA Modulates Frequency-Dependent Plasticity in Humans. ISCIENCE, 23, article no. 101657.

For guidance on citations see FAQs.

 \odot 2020 The Authors



https://creativecommons.org/licenses/by-nc-nd/4.0/

Version: Version of Record

Link(s) to article on publisher's website: http://dx.doi.org/doi:10.1016/j.isci.2020.101657 https://www.sciencedirect.com/science/article/pii/S258900422030849X?via=ihub

Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright owners. For more information on Open Research Online's data <u>policy</u> on reuse of materials please consult the policies page.


oro.open.ac.uk

iScience



Article

Metabolic Features of Mouse and Human Retinas: Rods versus Cones, Macula versus Periphery, Retina versus RPE



Li et al., iScience 23, 101672 November 20, 2020 © 2020 The Author(s). https://doi.org/10.1016/ j.isci.2020.101672

iScience

Article

Metabolic Features of Mouse and Human Retinas: Rods versus Cones, Macula versus Periphery, Retina versus RPE

Bo Li,^{1,2,6} Ting Zhang,^{3,6} Wei Liu,^{4,5} Yekai Wang,¹ Rong Xu,¹ Shaoxue Zeng,³ Rui Zhang,³ Siyan Zhu,¹ Mark C. Gillies,³ Ling Zhu,³ and Jianhai Du^{1,7,*}

SUMMARY

Photoreceptors, especially cones, which are enriched in the human macula, have high energy demands, making them vulnerable to metabolic stress. Metabolic dysfunction of photoreceptors and their supporting retinal pigment epithelium (RPE) is an important underlying cause of degenerative retinal diseases. However, how cones and the macula support their exorbitant metabolic demand and communicate with RPE is unclear. By profiling metabolite uptake and release and analyzing metabolic genes, we have found cone-rich retinas and human macula share specific metabolic features with upregulated pathways in pyruvate metabolism, mitochondrial TCA cycle, and lipid synthesis. Human neural retina and RPE have distinct but complementary metabolic features. Retinal metabolism centers on NADH production and neurotransmitter biosynthesis. The retina needs aspartate to sustain its aerobic glycolysis and mitochondrial metabolism. RPE metabolism is directed toward NADPH production and biosynthesis of acetyl-rich metabolites, serine, and others. RPE consumes multiple nutrients, including proline, to produce metabolites for the retina.

INTRODUCTION

Retinal photoreceptors need an enormous supply of ATP, reducing equivalents and other metabolites to maintain visual transduction and renew their daily-shed outer segments (Hurley et al., 2015; Leveillard and Sahel, 2017; Okawa et al., 2008). Mutations of metabolic genes or defects in metabolic processes have a role in many common degenerative retinal diseases such as inherited retinal degeneration, diabetic retinopathy, and age-related macular degeneration (AMD) (Ferrington et al., 2020; Leveillard and Sahel, 2017; Narayan et al., 2017).

Like tumors, retinas are known for aerobic glycolysis, also called the Warburg effect (Hurley et al., 2015). Aerobic glycolysis can produce large amounts of lactate from glucose, even in the presence of O₂. It is estimated that 80%–96% of glucose in isolated retinas is converted into lactate and only a small fraction is oxidized in the mitochondria (Hurley et al., 2015). Recent studies confirm that mammalian retinas strongly express enzymes associated with the Warburg effect such as the M2 isoform of pyruvate kinase, hexokinase 2, and lactate dehydrogenase A (Casson et al., 2016; Lindsay et al., 2014; Petit et al., 2018; Rajala et al., 2013; Rueda et al., 2016). However, retinas are also densely packed with mitochondria, which consume oxygen rapidly (Hoang et al., 2002; Narayan et al., 2017). Since glucose is the putative primary nutrient for the retina, it remains unclear how the retina supports its active mitochondrial metabolism while converting most of its glucose to lactate.

Rods and cones are the two major types of photoreceptors in the retina. Rods are responsible for dimly lit vision, whereas cones are for high acuity, central vision, and color vision. Cones are highly enriched in the center of the retina, called the macula, in humans and some birds. Cone photoreceptor degeneration is the ultimate cause of clinically significant vision loss in conditions such as AMD (Hoang et al., 2002; Narayan et al., 2017). Cones expend more energy than rods (Johnson et al., 2007; Perkins et al., 2003), but we still know very little about their metabolism compared with rods. The study of cone metabolism is challenging, since cones account for only 2%–3% of photoreceptors in mice and rodents do not have the macula. The recent development of all-cone mice by deletion of neural retina leucine zipper (*Nrl*), a gene required for

¹Departments of

Ophthalmology and Biochemistry, West Virginia University, WVU Eye Institute, One Medical Center Dr, PO Box 9193, Morgantown, WV 26506, USA

²Department of Ophthalmology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu Province 225100, China

³Save Sight Institute, Sydney Medical School, University of Sydney, Sydney, NSW 2000, Australia

⁴Department of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine, Bronx, NY 10461, USA

⁵Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA

⁶These authors contributed equally

⁷Lead Contact

*Correspondence: jianhai.du@wvumedicine.org https://doi.org/10.1016/j.isci. 2020.101672

1



rod development (Daniele et al., 2005; Mears et al., 2001), and cone-rich human retinal organoids (Kim et al., 2019) facilitate cone research. To investigate cone photoreceptor metabolism, we used all-cone mice, cone-rich retinal organoids, and human macula from postmortem donors in this study.

Photoreceptors rely on metabolic support from their neighboring retinal pigment epithelium (RPE). Disruption of RPE metabolism contributes to photoreceptor degeneration (Ferrington et al., 2020; Fisher and Ferrington, 2018). Inhibition of RPE mitochondrial metabolism is sufficient to cause AMD-like retinal degeneration in mice (Han et al., 2020; Kurihara et al., 2016; Zhao et al., 2011). Conversely, impairment of photoreceptor metabolism also influences RPE health (Brown et al., 2019). Accumulating evidence supports the concept that photoreceptors and RPE form an interdependent metabolic ecosystem (Bisbach et al., 2020; Brown et al., 2019; Kanow et al., 2017; Reyes-Reveles et al., 2017; Wang et al., 2019). Photoreceptors shed lipid-rich outer segment discs and export lactate due to the Warburg effect; the RPE converts the outer segment discs into ketone bodies to fuel photoreceptors and it utilizes lactate to preserve glucose for photoreceptors(Adijanto et al., 2014; Reyes-Reveles et al., 2017). We have also reported that reductive carboxylation (reversed TCA cycle) is a very active metabolic pathway in RPE, which it prefers to fuel with proline (Chao et al., 2017; Du et al., 2016). Proline-derived intermediates, including citrate, glutamate, and aspartate, can be exported by RPE to fuel retinal mitochondria (Yam et al., 2019). However, most of these studies come from cultured RPE cells and mice. Native human RPE are more dense and multinucleated in the macula than in the periphery (Rashid et al., 2016; Starnes et al., 2016). The macular RPE is where AMD starts, but the metabolic differences between the RPE of the macula and the peripheral retina, and their symbiotic relations with the corresponding neural retinal regions, are still unknown.

We used a targeted metabolomics approach in this study to analyze consumed and released metabolites in the media from cone-rich human retinal organoids, rod-dominant versus all-cone mouse retinas, human macular versus peripheral neural retinas, and human macular versus peripheral RPE/choroid. By integrating our results with the analysis of the expression of metabolic genes, we have identified key metabolic features of retinal organoid development, rods versus cones, macula versus periphery, and neural retina versus RPE. These features may elucidate the different metabolic needs of retinal mitochondria, cones, and human macula and reveal the metabolic communications between human retina and RPE at the macula and peripheral retina.

RESULTS

Metabolite Consumption and Metabolic Gene Expression in Human Cone-Rich Retinal Organoids

Cell differentiation in retinal organoids largely recapitulated transcriptomic and electrophysiological properties of retinogenesis in vivo (Kim et al., 2019). Retinal organoids at D56 were mainly composed of retinal progenitor cells and early differentiated retinal cells, whereas retinal organoids at D296 were mostly composed of maturing cones, rods, and Müller glial cells (Kim et al., 2019). To study the nutrient needs during the development of the human retina, we collected spent media 48 h after the medium change from human retinal organoids on 56 days (D56) and 296 days (D296) (Figure 1A). Blank media without cells in the same culture plate for 48 h served as baseline control. We targeted 219 metabolites covering major nutrients and pathways (Table S1) and detected 89 metabolites from these media. To determine metabolite uptake and release, we divided the ion abundance from organoids by those from the control media (see details in Transparent Methods). Retinal organoids at both D56 and D296 consumed glucose, cystine, and cystathionine (Figures 1B and 1C). Retinal organoids at D56 used L-Alanyl-Glutamine (GlutaMAX), hypoxanthine, lysine, hippurate, glycerol, and biotin, but D296 did not (Figures 1B-1D). Surprisingly, retinal organoids at D296 consumed 6- to 8-fold more aspartate and glutamate from the media, but organoids at D56 did not use them at all (Figures 1B and 1C). These results indicate that the consumption of aspartate and glutamate is specific for mature retinal cells. Additionally, retinal organoids at D296 also consumed histamine. Glucose can be metabolized through glycolysis and the mitochondrial TCA cycle into lactate, pyruvate, and other mitochondrial intermediates. GlutaMAX could be hydrolyzed into glutamine and alanine. As expected, the products from glucose and GlutaMAX, including lactate, pyruvate, alanine, glutamine, proline, citrate, and other metabolites, were produced significantly by D56 organoids (Figure 1E). D296 organoids generated similar amounts of lactate and pyruvate as D56 organoids, but they produced ~11-fold of hypotaurine and 2-fold of acetyl-carnitine (C2-carnitine) (Figures 1F and 1G).

Small molecule transporters and metabolic enzymes contribute to specific profiles in metabolite uptake and release. To compare the expression of transporters and enzymes, we curated 2,764 classic metabolism

iScience Article






Figure 1. Metabolite Consumption and Metabolic Gene Expression in Human Cone-Rich Retinal Organoids (A) Schematic for profiling medium metabolites in retinal organoid culture. Retinal organoids on Day 56 (D56) and D296 were cultured in a medium (see Transparent Methods) for 48 h. The spent media were analyzed for metabolite consumption or release, and the medium in culture wells without retinal organoids was used as a control. (B–D) Metabolite consumption in retinal organoids. Metabolite uptake in retinal organoids at (B) 56 days and (C) 296 days. (D) The comparison of metabolite uptake between D56 and D296 retinal organoids. Data were relative ion abundance over the control. N = 3, *p < 0.05 versus Control or D56 organoids. Data are represented as mean \pm SEM. t test. (E–G) Metabolite release from organoids. Metabolite release in retinal organoids at (E) 56 days and (F) 296 days. (G) The comparison of metabolite release between D56 and D296 retinal organoids. Data were relative ion abundance over the control. N = 3, *p < 0.05 versus Control or D56 organoids. Data are represented as mean \pm SEM. t test. (H) A schematic of nutrient uptake and release in retinal organoids. Increased metabolites in mature organoids at D296 are colored in red and increased metabolites in D56 organoids are colored in green.

(I) Heatmap of gene expression of top-ranked small molecule transporters in the human retinal organoids cultured at 1-, 3-, 6-, and 9-month stages. FPKM values of bulk RNA sequencing (Kim et al., 2019) was used for plotting.

See also Figure S1 and Tables S2, S3, and S6.





genes from KEGG pathways (Table S2) and analyzed their expression in the transcriptome of retinal organoids at stages between 1 and 9 months (Kim et al., 2019). Differentially expressed genes along the time course of human retinal organoids identified previously (Kim et al., 2019) were intersected with the genes in metabolic pathways, resulting in 378 metabolic genes that were differentially expressed during the development of retinal organoids. More than half of the differentially expressed genes were ion and small molecule transporters (Figure S1A, Table S3). Remarkably, glutamate and aspartate transporters including solute carrier 1A3 (SLC1A3), SLC17A7, SLC1A7, and SLC1A2 were the most highly enriched of the upregulated small molecule transporters in 9-month organoids (Figure 1H and Table S3). These results indicate that mature retinal organoids need more aspartate and glutamate. Other amino acids, bicarbonate, and water transporters were also upregulated in the maturing organoids. Glucose transporter 1 (SLC2A1), the major glucose transporter, was expressed similarly during organoid development except for a decrease at 3 months. Monocarboxylate transporter (MCT) is the major lactate/pyruvate transporter in the retina, and MCT4 or SLC16A3 was expressed similarly between 3- and 9-month organoids (Figure 1H). These results were consistent with our metabolite consumption data on glucose and lactate. Glutamate decarboxylase 1 and 2 (GAD1/2) convert glutamate into 4-aminobutyrate (GABA) (Figure 1I). They were highly upregulated in D296 organoids (Figure S1B), providing further evidence of the need for glutamate. GABA transporters were also increased in the mature organoids (Table S3). Genes in cysteine, cystathionine, glutathione, and histidine/histamine metabolism were highly enriched in the mature organoids (Figure S1B). This may implicate in the changed consumption of cysteine derivatives such as cystine, hypotaurine, and histamine. Apart from aspartate and glutamate metabolism, most upregulated genes in mature retinal organoids were involved in glycan, glycolysis, lipids, ATP-binding cassette (ABC) transporter (lipid transporter), and nucleotides, especially cyclic nucleotides and purine degradation (Figures S1C-S1E, Table S3). Increased purine degradation and recycling may be the cause of the reduced consumption of hypoxanthine that we observed (Figures 1D and 1I). To sum up, retinal organoids showed distinctive features of nutrient consumption and developmentally regulated expression of metabolic genes. Mature retinal organoids may import and utilize aspartate and glutamate through their upregulated transporters for neurotransmitter synthesis and energy metabolism (Figure 1I).

Metabolite Consumption and Metabolic Gene Expression of Rod-Dominant and All-Cone Mouse Retinas

Rods comprise ~97% of photoreceptors in mouse retinas. Knockout (KO) of Nrl converts all rods into conelike photoreceptors (Mears et al., 2001) to make all-cone retinas. We cultured retinas from ~1-month-old Nrl-heterozygous (Het) (rod-dominant similar to wild type [WT]) mice and Nrl KO mice in transwells and analyzed metabolites in the media after culturing for 24 h (Figure 2A). Compared with the control media, 32 metabolites from Nrl Het and 37 metabolites from Nrl KO media were significantly different (Figures 2B-2H). Most changed metabolites were in a similar pattern in the Het and KO retinas. Interestingly, aspartate and glutamate were among the most consumed metabolites in both Het and KO retinas, with a decrease of 8- to 11-fold compared with baseline media (Figures 2B and 2C). Additionally, both Het and KO retinas consumed glucose, amino acids, carnitine, and intermediates in mitochondrial metabolism including citrate, succinate, and fumarate (Figures 2B and 2C). Like retinal organoids, mouse retinas excreted large amounts of lactate, acetylcarnitine, and 1-methyladenosine (Figures 2E and 2F). However, mouse retinas also released nucleosides, other acyl-carnitines, amino acids, and derivatives from amino acids such as creatine and creatinine (Figures 2E and 2F). Isopentenyl pyrophosphate (IPP), an intermediate of the mevalonate pathway, was not detected in the control media but was significantly increased in the spent media of mouse retinas, especially the NrI KO group (Figure 2G). These results indicate that mouse retinas have very active mitochondrial, lipid, and nucleotide metabolism.

Twelve metabolites were different between Het and *Nrl* KO retinas (Figures 2D and 2G–2H). *Nrl* KO consumed more pyruvate and cystathionine and produced more lactate, acylcarnitines, creatine, and 1-methyladenosine (Figures 2D, 2G–2H). In contrast to retinal organoids, neither *Nrl* Het nor KO retinas excreted hypotaurine; however, mouse retinas exported more taurine, particularly the Het retinas (Figure 2H). Ketone bodies are important alternative fuels for neurons. Intriguingly, only rod-dominant retinas produced the ketone body, 3-HB (Figures 2E–2H), suggesting that there might be interdependent ketone body utilization between rods and cones.

We then analyzed the expression of metabolic genes from a transcriptome database of WT and *Nrl* KO retinas (Brooks et al., 2011). Among the most abundant small molecule transporters ranked by either WT or KO

iScience Article






Figure 2. Metabolite Consumption and Metabolic Gene Expression in Nrl Het (Rod-Dominant) and Nrl KO (allcone) Mouse Retina

(A) Schematic for profiling medium metabolites in mouse retinal explants. Retinas from *Nrl* Het and *Nrl* KO mice were dissected, placed in transwells, and maintained in culture for 24 h. The culture media without retinas were the baseline control. All media metabolites were analyzed by targeted metabolomics.

(B–D) Metabolite consumption from mouse retinal explants. Metabolite uptake in (B) Nrl Het and (C) Nrl KO retinas. (D) The comparison of metabolite uptake between Nrl Het and Nrl KO retinas. Data were relative ion abundance over the control or Nrl Het. N = 6, *P < 0.05 versus Control or Nrl Het retinas. Data are represented as mean \pm SEM. t test.

(E–H) Metabolite release from mouse retinal explants. Metabolite release in (E) Nrl Het and (F) Nrl KO retinas. (G and H) The comparison of metabolite uptake between Nrl Het and Nrl KO retinas. Data were relative ion abundance over the control or Nrl Het or absolute ion abundance when those metabolites were not detected in the baseline control. N = 6, *P < 0.05 versus Control or Nrl Het retinas. Data are represented as mean \pm SEM. t test.

(I) Gene expression of the top 20 abundant small molecule transporters in the NrI KO and Het mouse retinas.

(J) Schematic of nutrient uptake and release in Nrl KO retinas. Metabolites with enhanced uptake or release in Nrl KO retinas are colored red. Upregulated genes in Nrl KO are colored brown. Glu/Asp represents transporters for glutamate and aspartate.

See also Figures S2–S3 and Tables S2, S4, S7, and S10.





retinas, transporters for glutamate and aspartate were among the most enriched (Figures 2I and S2). In particular, *Slc17a7* had more abundant transcripts than the other small molecule transporters (Figures 2I and S2). Transporters for glucose, GABA, glutamine, lactate, pyruvate, and ketone bodies were also among the top transporters. Compared with WT, 800 metabolic genes were changed, with 401 upregulated in *Nrl* KO retinas (Figure S3, Table S4). Ion transport, lipid metabolism, small molecule transport, glycan, amino acid, nucleotide, and sugar metabolism were the major changed pathways (Figure S3). Key enzymes in glycogen metabolism (*Pygm, Gaa*), pyruvate metabolism (*Pcx, Pdha1, Me1*), TCA cycle (Cs, *Acly, Ogdh, Idh3a*), cysteine/cystathionine metabolism (*Suox, Ado, Cdo1, Gclm*), and fatty acid synthesis (*Acaca, Acacb, Oxsm, Elovl6*) were significantly upregulated in *Nrl* KO retinas (Figures 2J and Table S4). These data support the nutrient uptake and release results, indicating that cone photoreceptors require more pyruvate and other nutrients for their robust mitochondrial TCA cycle, lipid synthesis, and amino acid metabolism (Figure 2J).

Metabolite Consumption and Metabolic Gene Expression of Human Peripheral and Macular Retina

To investigate the nutrient utilization of the human macula and peripheral retina, we cultured human neural retinal explants punched from the macular and peripheral regions from the same donor (Figure 3A). Human donors had no known retinal diseases, and postmortem fundus photographs showed no abnormalities (Figures 3A and Table S5). After culturing for 24 h, media levels of 52 metabolites in the peripheral retina and 51 metabolites in the macula were significantly different (Figures 3B–3H and S4). Strikingly, aspartate and glutamate were almost completely depleted in spent media from both peripheral retina and macular punches (Figures 3B and 3C). Aspartate and glutamate were supplemented at \sim 0.15 mM in all the media of retinal cultures, and they were depleted in mature retinal organoids, mouse retinas, and human retinas (Tables S6-S8). These findings demonstrate that retinas need substantial amounts of aspartate and glutamate. As well as glucose, carnitine, and amino acids, human retinas also actively consumed vitamins such as panto then ic acid, nicotinamide, and biotin (Figures 3B–3D and S4). β -Alanine, which can be metabolized into acetyl-CoA in mitochondria, was also reduced 2- to 3-fold in the media. Similar to mouse retinas, both macular and peripheral retinas released lactate, nucleosides, and acylcarnitines, confirming that human retinas are very active in metabolizing glucose, amino acids, and lipids (Figures 3E-3G and S4). Creatine, creatinine, and citrulline increased 3- to 7-fold in the media with retinal cultures (Figures 3E-3G). These metabolites, synthesized from arginine, are involved in the synthesis and degradation of the high-energy metabolite phosphocreatine. IPP, guanosine, kynurenine, and N1-methylnicotinamide were not detected in the control media but significantly increased in spent media from both macular and peripheral neural retinas (Figure 3G). These results confirm that the mevalonate pathway, purine catabolism, and NAD metabolism are active in the retina.

Twenty-five metabolites in the media were significantly different between the macular and the peripheral retina (Figures 3D and 3G–3H). In general, the neural macula consumed and released more metabolites than the peripheral retina except for succinate, betaine, and kynurenine (Figures 3D and 3G–3H). Like cone-dominant *Nrl* KO retinas, the neural macula consumed more pyruvate from the media and released more lactate, acetylcarnitine, 1-methyladenosine, and creatine into the media. These data suggest that the neural macula has more active energy metabolism than the peripheral retina. In support of this, the neural macula released more nucleosides and several TCA cycle intermediates than the peripheral retina (Figure 3H).

To further understand the genetic basis for this differential nutrient consumption, we analyzed the expression of metabolic genes in a human transcriptome database (Whitmore et al., 2014). As in the mouse retinas, aspartate and glutamate transporters were highly enriched among the most abundant small molecular transporters in both the macula and peripheral retina, with *SLC17A7* being the most abundant of all (Figures 3I and S5). Transporters for glucose, glutamine, taurine, creatine, lactate, and pyruvate were also among the most abundant transporters (Figures 3I and S5). Metabolic gene analysis found 307 upregulated and 192 downregulated genes in neural macula, compared with peripheral retina (Table S9). Similar to mouse *Nrl* KO retinas, the most changed pathways were in ion transport, small molecule transport, lipid, glycan, amino acid, nucleotide, and sugar metabolism (Figure S6). Changed small molecule transporters were enriched for the transport of sugar, glutathione, glycine, serine, arginine, citrulline, and glutamate (Figure S6). Glycan, a polysaccharide that conjugates with lipid and protein to make the cell membrane, is synthesized mostly from glucose and fructose. Strikingly, most genes in glycan synthesis








Figure 3. Metabolite Consumption and Metabolic Gene Expression in the Human Macular and Peripheral Retina (A) Schematic diagram of human macular and peripheral explant culture. Macula and Peripheral punches from neural retinas or their corresponding RPE/choroid punches were cultured on inserts in transwell plates for 24 h. Representative fundus images from one donor showed healthy retinas. Representative images of cultured macular and peripheral neural retinas and RPE/choroids in transwell plates.

(B–D) Metabolite consumption from human neural retinal explant culture. Metabolite uptake from (B) peripheral and (C) macular retinal explants. (D) The comparison of metabolite uptake between macular and peripheral retinal explants. Data were relative ion abundance over the control or peripheral retinas. N = 8, *P < 0.05 versus Control or peripheral retinas. Data are represented as mean \pm SEM. t test.

(E–H) Metabolite release from human neural retinal explant culture. Metabolite release from (E) peripheral and (F) macular retinal explants. (G and H) The comparison of metabolite release between macular and peripheral retinal explants. Data were relative ion abundance over the control or peripheral retinas, or absolute abundance when detected in the baseline control. N = 8, *P < 0.05 versus Control or peripheral retinas. Data are represented as mean \pm SEM. t test.

(I) Gene expression of the top 20 abundant small molecule transporters in human peripheral and macular retinas.
(J) Schematic of nutrient uptake and release in macular retinas. Metabolites with enhanced uptake or release in macular retinas are colored red. Upregulated genes in macular retinas are colored brown. Glu/Asp represents transporters for glutamate and aspartate.

See also Figures S4–S6 and Tables S2, S5, S8, S9, and S10.





were upregulated in the macula, but genes responsible for its degradation were downregulated, indicating the neural macula requires more exogenous glucose to meet the high demand for glycans.

Key enzymes in several major metabolic pathways were significantly upregulated in the macula compared with the peripheral retina such as those responsible for glycogen metabolism (*PYGM, PYGB, GBE1, UGP2*), pyruvate metabolism (*PC, ME2, LDHB, LDHD*), TCA cycle (*OGDH, ACLY, MDH1, ACO1, SDHA*), fatty acid synthesis (*ACACA, ACSS2, FASN, ELOVL6*), mevalonate and cholesterol metabolism (*ID11, HMGCR, HMGCS1*), ketone body metabolism (*OXCT2, HMGCLL1*), and NAD synthesis (*QPRT, NMNAT2*) (Table S9, Figure 3J). These upregulated pathways in human neural macula were similar to all-cone *Nrl* KO retinas. By comparing the changed metabolic genes in *Nrl* KO with the human macula, we found 119 of 177 genes were changed in the same way, including those in the major metabolic pathways (Table S10). These results indicate that all-cone mouse retinas have some metabolic similarities with the cone-enriched human macula. Notably, pyruvate was the only nutrient that was consumed more by both *Nrl* KO retinas and human macula. Pyruvate carboxylase (*PC* in human and *Pcx* in mouse), which utilizes pyruvate for TCA cycle and gluconeogenesis, was also increased in both *Nrl* KO retinas and macular retinas (Figure 3J). These data demonstrate that the neural macula meets its higher metabolic requirements by utilizing more glucose and pyruvate for the TCA cycle and synthesis of glycan, glycogen, and lipids.

Metabolite Consumption and Metabolic Gene Expression in Human Peripheral and Macular RPE/Choroid

The RPE, tightly bound to the choroid, is critical to transport metabolites to and from the retinas. To understand the metabolic communications between retina and RPE, we studied the nutrient uptake and release of punches of human RPE/choroid using the same donor eyes from the neural retinal experiments (Figure 3A). The profiles of consumption and release by human RPE/choroid punches from both macula and periphery were similar to those of our previously reported studies of human RPE *in vitro* (Chao et al., 2017) but quite different from those in human retinas (Figures 4A–4G and S7). As well as specific nutrients in the media, such as carnitine, nicotinamide, cysteine, and proline, human RPE/choroid also consumed nutrients not specified in the medium formula such as N-acetylglycine, erythritol, and succinate (Figures 4A and 4B). These metabolites may come from serum and other supplements in the media. In contrast to neural retinas, RPE/choroid did not consume glutamate, and only the macular RPE used a small amount of aspartate (<1.5-fold), confirming that the consumption of glutamate and aspartate is specific to the neural retina. In contrast to human neural retinas, human RPE/choroid consumed, rather than excreted, taurine and betaine (Figures 4D–4G and S7), suggesting that the neural retina and RPE might exchange these metabolites.

As well as lactate, nucleosides, and acylcarnitines, RPE/choroid from both macula and periphery exported considerable amounts of citrate, isocitrate, 3-HB, and cholesterol (Figures 4D and 4E), supporting previous reports (Adijanto et al., 2014; Reyes-Reveles et al., 2017) that RPE actively metabolizes lipids. Compared with their corresponding neural retinas, RPE/choroid exported ~40 times more N1-methylnicotinamide (methylated from nicotinamide), indicating that RPE/choroid has highly active nicotinamide catabolism (Figure 4F). Additionally, RPE/choroid released serine, β -alanine, and glycerol, which were consumed by the human neural retinas (Figures 4D–4E and S7), providing further evidence for metabolic communication between the neural retina and the RPE.

The peripheral RPE/choroid punches consumed and released significantly more metabolites than the macular punches (Figures 4 and S7). However, the macular punches generally consumed or released more of the changed metabolites that they had in common with the peripheral RPE/choroid punches (Figures 4C and 4G). The macular RPE/choroid punches utilized more nicotinamide, erythritol, and glucose than their peripheral counterparts (Figure 4C). Erythritol comes from either additives or endogenous synthesis from glucose. It can be metabolized into erythronic acid, which is abundant in human aqueous humor (Harding et al., 1999). RPE/choroid punches from the macular region also released more N1-methylnicotinamide, malate, β -alanine, and ornithine, which may have been derived from the methylation of nicotinamide and glucose catabolism (Figures 4F, 4G, and 4I).

Unlike neural retinas, no aspartate/glutamate transporters were found in the top 20 most abundant small molecule transporters in the RPE/choroid (Figures 4H and S8). The abundance of small molecule transporters was generally higher in the peripheral RPE than the macula, supporting our data that there were more changed metabolites in the periphery. MCTs for lactate, pyruvate, and ketone bodies and

iScience Article






Figure 4. Metabolite Consumption and Metabolic Gene Expression in Human Macular and Peripheral RPE/ Choroids

(A–C) Metabolite consumption from human RPE/choroid explant culture. Metabolite uptake from (A) peripheral and (B) macular RPE/choroid explants. (C) The comparison of metabolite uptake between macular and peripheral RPE/choroid explants. Data were relative ion abundance over the control or peripheral RPE/choroid explants. N = 8, *P < 0.05 versus Control or peripheral RPE/choroid explants. Data are represented as mean \pm SEM. t test.

(D–G) Metabolite release from the macular and peripheral RPE/choroid explant culture. Metabolite release from (D) peripheral and macular (E) RPE/choroid explants. (F–G) The comparison of metabolite uptake between macular and peripheral RPE/choroid explants. Data were relative ion abundance over the control or peripheral RPE/choroid explants, or absolute abundance when detected in the baseline control. N = 8, *P < 0.05 versus Control or peripheral RPE/choroid explants. Data are represented as mean \pm SEM. t test.

(H) Gene expression of the top 20 abundant small molecule transporters in human peripheral and macular RPE/choroid.
 (I) Schematic of nutrient uptake and release in macular RPE/choroid. Red-colored metabolites are those with increased uptake or release in macular RPE/choroid. ABC transporters and glucose transporters (SLC5A9 and SLC2A4) are upregulated in macular RPE/choroid.

See also Figures S7–S9 and Tables S2, S5, S11, and S16.








Figure 5. Comparison of Metabolite Consumption and Metabolic Genes between Human Retinas and RPE/ Choroids

(A) Differential metabolite consumption and release between human retinas and RPE/choroids. Metabolites are colored for changes over their baseline controls. Blue, metabolite consumption; red, metabolite release; and yellow, unchanged.

(B) Comparing gene expression in major metabolic pathways between human retinas and RPE/choroids. See also Figures S10–S11 and Tables S12, S13, and S14.

transporters for α -ketoglutarate, sugar, leucine, proline, and choline were abundant in peripheral RPE/ choroid (Figures 4H and S8), consistent with the altered uptake and release of these metabolites. The analysis of expression of metabolic genes found that there were 127 genes that were differentially expressed between macular and peripheral RPE/choroid (Table S11). The major altered pathways included lipid








Figure 6. A Proposed Model of Metabolic Communications between Human Retina and RPE/Choroid

Glucose transports through RPE from the choroid to the retina (bold green line). RPE strongly expresses genes in PPP, serine *de novo* synthesis, and one-carbon metabolism, which can use glucose to generate NADPH. The retina strongly expresses glycolic genes to produce lactate and NADH. The retina imports aspartate and glutamate through upregulated transporters (bold red line). Aspartate can be converted into OAA and malate to recycle NADH into NAD⁺ and bring electrons into mitochondria to produce ATP. Aspartate can also be used for the synthesis of glutamate, asparagine (ASN), N-acetylaspartate (Asp). The retina needs a large amount of glutamate for neurotransmission, the mitochondrial TCA cycle, and biosynthesis of GABA, glutathione (GSH), and glutamine (GIn) (bold blue line). RPE mitochondria use different substrates such as proline (yellow line), BCAAs, and lipids to synthesize NADPH and other metabolites that can be released to be used by the retina. Cone-rich retinas or human macula consumes more pyruvate (bold black line) for mitochondrial metabolism. Brown colored genes are upregulated genes in the retinas or RPE. See also Figure S11.

metabolism, transporters, and amino acid metabolism (Figure S9). Interestingly, genes involved in glycolysis and the TCA cycle were either decreased or unchanged in the macular RPE/choroid, whereas glucose transporters (*SLC2A4*, *SLC5A9*) were significantly increased (Table S11, Figures 4I and S9). Overall, genes in both lipid synthesis and lipid transporters were upregulated in the macular RPE/choroid punches compared with those from the peripheral RPE/choroid retina (Figure 4I).

Human Retina and RPE/Choroid Have Distinctive but Symbiotic Metabolic Features

To compare the metabolic features of the human retina and RPE/choroid, we studied the uptake and release of metabolites in the media from their cultures (Figures 3, 4 and 5A). We found 25 metabolites were consumed and released in the same pattern between retinas and RPE/choroid such as glucose, nicotinamide, carnitine, lactate, and inosine. Twenty-two metabolites were consumed or released only



by the neural retina, indicating these metabolites are neural retina specific. Sixteen metabolites were consumed or released only by RPE/choroid, indicating that they are RPE specific (Figure 5A). Interestingly, ten metabolites were consumed or released in opposite patterns, such as serine, ornithine, and β -alanine (Figure 5A), which were released by RPE/choroid but consumed by the neural retinas, suggesting that retinas and RPE are metabolically interdependent. Overall, we found neural retinas and RPE/choroid not only share some common pathways but also have their distinctive preferences in nutrient consumption and production.

About half of the 2,764 metabolic genes we studied were expressed differentially in human neural retinas versus RPE/choroids: 1,473 in the macula and 1,770 in the periphery (Tables S12 and S13). Transporters, lipids, glycan, amino acid, nucleotide, and sugar metabolism were again the major altered pathways between retinas and RPE/choroids (Figure S4). All genes involved in aspartate/glutamate transport and catabolism were upregulated in the neural retinas except aspartoacylase, which regenerates aspartate from Nacetyl-aspartate (Figures 5B and Table S13). This strongly suggests that retinas have a specific requirement for aspartate and glutamate, as summarized in Figure 6. More transporters for glucose, lactate, and pyruvate were found in RPE/choroid but they were also enriched in the retinas, indicating that these metabolites are essential nutrients for both tissues. As expected, neural retinas predominantly expressed genes involved in glycolysis to support their robust aerobic glycolysis (Figures 5B and S10, Table S14). Interestingly, many mitochondrial TCA cycle genes expressed different isoforms in neural retinas versus RPE/ choroid. For example, NAD⁺-dependent IDH3A/B, ADP-dependent SUCLA2, ACO2, and L2HGDH were predominantly expressed in the neural retinas, whereas NADP⁺-dependent IDH1/2, GDP-dependent SUCLG2, ACO1, and D2HGDH were mainly expressed in the RPE/choroid (Figure 6, Table S14). Notably, upregulated TCA cycle genes in the neural retinas were mostly NAD⁺ dependent. This differential expression suggests neural retinas and RPE have different roles in mitochondrial bioenergetics and biosynthesis. Strikingly, NADP(H)-associated pathways, including the pentose phosphate pathway (PPP) and one-carbon metabolism, were highly upregulated in the RPE/choroid compared with neural retinas (Figure 5B). Genes in serine synthesis were upregulated in RPE/choroid, but serine transporters were upregulated in the neural retinas. This was consistent with our findings that serine was released by RPE/choroid and consumed by retinas (Figures 5B and Table S14). Remarkably, genes involved in proline metabolism and nicotinamide/NAD metabolism were significantly upregulated in RPE/choroid, consistent with our findings that RPE/choroid consumed proline and nicotinamide. Many genes in amino acid metabolism pathways, such as those for cysteine, taurine, and citrulline, were partly upregulated in neural retinas or RPE/choroids, further indicating that there are symbiotic metabolic relationships between them (Figure 6).

DISCUSSION

We have compiled an atlas of nutrient consumption and utilization in human retinal organoids, mouse retinas, all-cone mouse retinas of Nrl KO, and human macular and peripheral retinas. By combining nutrient consumption with metabolic gene analysis, we have identified the following key features of neural retinal and RPE metabolism (Figure 6).

- Neural retinal metabolism centers on NADH-related metabolism for ATP production and the synthesis of neurotransmitters such as glutamate and GABA. The neural retina consumes glucose, aspartate, glutamate, citrate, nicotinamide, and other nutrients to sustain its active glycolysis, mitochondrial oxidative metabolism, and neurotransmitter synthesis.
- Cone-rich retinas and the neural macula have more active glycolysis and mitochondrial metabolism, through which they consume more pyruvate, than the rod-rich peripheral neural retina.
- Mature retinal organoids have aspartate/glutamate metabolism that is similar to the human neural retina.
- RPE/choroid metabolism centers on NADPH-related and acetyl-CoA metabolism for biosynthesis.
 RPE/choroid consumes glucose, proline, nicotinamide, BCAAs, and other nutrients for its activate PPP, reductive carboxylation, serine synthesis, one-carbon metabolism, citrate synthesis, ketone body synthesis, and cholesterol synthesis.
- Neural retinas and RPE/choroid have specific and complementary profiles in nutrient consumption and production that support their tight metabolic communications.

iScience Article



Uptake of aspartate and glutamate was a common feature in cone-rich retinal organoids and mouse and human retinas. Transporters and enzymes responsible for aspartate and glutamate metabolism were also highly enriched in the retina. Why do retinas actively consume aspartate and glutamate? Aspartate and glutamate are interconvertible by transamination with their ketoacids through GOT1/2 (Figure 6). We recently also reported that aspartate transamination is the primary pathway for the catabolism of aspartate and glutamate in mouse neural retinas (Xu et al., 2020). As a major neurotransmitter, glutamate is the most abundant amino acid in the retina (Kalloniatis et al., 1996; Marc et al., 1995). Retinal cells with the highest glutamate levels also have the highest aspartate levels (Kalloniatis et al., 1996). We have previously reported that aspartate is utilized robustly to provide both carbons and nitrogen groups for glutamate synthesis (Du et al., 2013; Lindsay et al., 2014; Xu et al., 2020). Notably, aspartate transamination also generates oxaloacetate (OAA), which can be converted to malate by cytosolic malate dehydrogenase (MDH1) to carry electrons into mitochondria through the malate-aspartate shuttle (Figure 6). This is important because it may help address the paradox of how the retina supports its active mitochondrial metabolism, whereas its metabolism relies on the Warburg effect that allows only a small proportion of pyruvate to be oxidized. MDH1 and GOT1 transcripts are more abundant than any other TCA cycle enzymes in both human and mouse neural retinas (Figure S11), supporting that aspartate catabolism is enhanced in the retina. Aspartate catabolism may (1) recycle NADH into NAD⁺ to sustain the highly active glycolysis, (2) provide cytosolic electrons for ATP production, (3) replenish mitochondrial OAA for biosynthesis, and (4) produce cytosolic and mitochondrial pyruvate through malic enzymes (Figure 6). Interestingly, low glucose or inhibition of glucose oxidation could cause massive accumulation of aspartate in the neural retina with severe depletion of glutamate (Du et al., 2013; Grenell et al., 2019; Zeevalk and Nicklas, 2000). Therefore, aspartate utilization supports active glycolysis, mitochondrial metabolism, and glutamate synthesis. Additionally, aspartate is an immediate precursor for asparagine and N-acetylaspartate (NAA), both of which are important for neuronal function (Ramos et al., 2011; Ruzzo et al., 2013) (Figure 6). Deficiency of the mitochondrial aspartate/glutamate carrier 1(AGC1) reduces aspartate and NAA, resulting in brain defects and impaired visual function (Contreras et al., 2016; Jalil et al., 2005; Ramos et al., 2011).

Besides being a neurotransmitter, glutamate is an important substrate for the TCA cycle and the synthesis of glutamine and glutathione (Figure 6). Decreased glutamate availability substantially reduces the levels of glutamine and glutathione (Grenell et al., 2019). Glutamate also serves as a major nitrogen donor to synthesize non-essential amino acids by transaminases and is a precursor for GABA by decarboxylation (Figure 6). Consistently, glutamate alanine transaminase and glutamate decarboxylases are strongly expressed in the neural retina (Whitmore et al., 2014). Blood levels of aspartate and glutamate are quite low (Dasarathy et al., 2010; Hui et al., 2017); it remains unclear how they are transported across retina-blood barriers. RPE may be a source of aspartate and glutamate for the retina. We have reported that RPE can metabolize glucose and proline into glutamate and aspartate, which are exported to be used by the retina (Chao et al., 2017; Yam et al., 2019). Notably, glutamate content decreases in cone photoreceptors overlying RPE defects in atrophic AMD (Jones et al., 2016). There is a moderate expression of multiple transporters for aspartate and glutamate in the RPE (Whitmore et al., 2014).

Cones are known to have much higher energy needs than rods (Korenbrot, 2012). It is postulated that mitochondrial metabolism may support the extra energy demand, as cones have 2-10 times more mitochondria and 3 times more cristae membrane surface than rods (Hoang et al., 2002; Perkins et al., 2003, 2004). The generation of higher lactate, acetylcarnitine, and IPP (synthesized from acetyl-CoA) in both all-cone mouse retinas and the neural macula, which is cone-rich, provides strong evidence that cones are more metabolically active than rods. We also found all-cone neural retinas and macula consume more pyruvate than the peripheral neural retina, which is rod dominant. This may explain how cones fuel their abundant mitochondria even when they have active aerobic glycolysis. The SLC16A3 (MCT4), which has low affinity for pyruvate in order to preserve intracellular pyruvate levels (Bergersen, 2015), is strongly expressed in the neural macula (Table S9). Inhibition of pyruvate utilization causes visual impairment in mice and fish due to photoreceptor degeneration (Grenell et al., 2019; Taylor et al., 2004). Pyruvate provides metabolic advantages that enhance both glycolysis and mitochondrial metabolism. Pyruvate can regenerate NAD⁺ through lactate dehydrogenase to stimulate glycolysis. Mitochondria need a constant supply of acetyl groups from acetyl-CoA and OAA to synthesize citrate to sustain the TCA cycle for oxidative and biosynthetic metabolism (Figure 6). Pyruvate provides both acetyl groups and OAA through pyruvate dehydrogenase and PC. The neural retina can also use fatty acids and ketone bodies, but these nutrients only provide acetyl groups (Joyal et al., 2018; Reyes-Reveles et al., 2017). Consistently, pyruvate carboxylase expression was



upregulated in both all-cone retinas and neural macula. Hepatic deletion of *PC* in mice diminishes TCA cycle intermediates, especially aspartate, and depletes NADPH and glutathione (Cappel et al., 2019). PPP is the classic pathway to generate NADPH for the regeneration of visual pigment, but its activity is very low in the neural retina and photoreceptors (Adler et al., 2014; Futterman and Kinoshita, 1959; Winkler et al., 1986). The regeneration of visual pigment in cones is at least 100 times faster than rods (Chen et al., 2009). Pyruvate could stimulate PPP activity 15 times in isolated neural retinas (Futterman and Kinoshita, 1959) and may contribute to the high demand for NADPH in cones. Pyruvate also increases the availability of glutamate and glutamine *in vitro* (Gamberino et al., 1997; Lieth et al., 2001). We have reported that retinal deletion of the mitochondrial pyruvate carrier leads to the accumulation of pyruvate and aspartate but the depletion of glutamate, glutamine, and glutathione results in retinal degeneration (Grenell et al., 2019). Interestingly, pyruvate supplementation prevents light-induced retinal degeneration (Natoli et al., 2016; Ren et al., 2011; Sato et al., 2020). Further research is warranted to determine whether increasing pyruvate utilization by supplementation or genetic approaches might have a neuroprotective effect on the macula.

The RPE is closely coupled with photoreceptors in nutrient utilization (Han et al., 2020; Kanow et al., 2017; Revelse et al., 2017; Xu et al., 2020). In agreement with other studies of RPE cells (Chao et al., 2017; Xu et al., 2020; Yam et al., 2019), we found that human RPE/choroid explants consumed glucose, proline, nicotinamide, and BCAAs and released plenty of 3-HB, citrate, and cholesterol. All these released metabolites are made from acetyl-CoA, indicating that RPE mitochondria function like mitochondria in the liver that oxidize nutrients to support other tissues. Interestingly, retinas could readily utilize the released 3-HB, citrate, and cholesterol for bioenergetics and biosynthesis (Chao et al., 2017; Futterman and Kinoshita, 1959; Grenell et al., 2019; Reyes-Reveles et al., 2017; Tserentsoodol et al., 2006). The different consumption of metabolites by the neural retina and RPE/choroid suggests an important metabolic coupling between them. For example, RPE released serine, but the retina consumed serine. Serine is an essential precursor for phospholipid synthesis and one-carbon metabolism. Photoreceptors require active phospholipid biosynthesis to renew their daily shedding of outer segments, but enzymes for serine synthesis are highly expressed in RPE (Figure 5B) (Sinha et al., 2020). The uptake of serine by our neural retinal cultures and upregulated serine transporters sideroflexin 1/3 (SFXN1/3) in the neural retina further suggest that retinas need exogenous serine. Mutations of SFXN3 leads to progressive outer retinal degeneration (Chen et al., 2020). Remarkably, low serine from the RPE may account for the synthesis of toxic deoxysphingolipids in the degenerative macular condition, macular telangiectasia type 2 (Gantner et al., 2019).

In summary, profiling nutrient uptake and release by tissue explants provides a useful platform to investigate tissue-specific and inter-tissue metabolism and to functionally annotate the ever-increasing tissuespecific metabolic transcriptome. By profiling mouse and human retinal explants, we reveal distinctive metabolic features in progenitor versus differentiated retinal organoids, mouse rod versus cone-retinas, and human peripheral neural retina versus the neural macula. These findings provide a resource of basic information for future studies on the retina and RPE metabolism.

Limitations of the Study

Traditional culture media were used for our organoid and retinal explant culture. These media may not reflect the microenvironment *in vivo*. For example, no lactate was included in these media, but RPE in an eye may be exposed to high amounts of lactate from the neural retina. A recent study showed that RPE can uptake lactate to preserve glucose for photoreceptors (Kanow et al., 2017). Future investigation of metabolite concentrations in choroid and vortex veins will be important for developing a medium formulation that more accurately mimics *in vivo* conditions. Additionally, the glucose concentrations in our culture were higher than physiological conditions owing to the limitation of traditional static culture. A microfluidic perifusion with a physiological concentration of glucose is under exploration to optimize human retinal explant culture. Our human RPE explant culture provides information for metabolite uptake and release, but it cannot be used to study metabolite transport because the RPE explant only covers part of the transwell membrane and there is no biological barrier between the upper and lower chamber. Human neural retinal explants cultured together with human RPE cells can be investigated with stable-isotope tracers to understand metabolite transport and communication between neural retina and RPE. Cone-like photoreceptors in *Nrl* KO eyes may still be different from mature cones in wild animals. Future studies on cone-rich animals such as squirrels, fish, and chicken will help to validate our findings on cone-specific





metabolism. A limitation of our targeted metabolomics analysis is that we reported the ion abundance, not absolute abundance. Evaluation of absolute abundance will require labeled internal standard for each metabolite to avoid matrix effect in the mass spectrometry analyses. Future technical improvements in our analysis procedure will focus on determining the absolute concentration of many of the key metabolites in retinas and RPE. Finally, the human retinas from our explant culture underwent postmortem delay, which can influence metabolism in these tissues.

Resource Availability

Lead Contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jianhai Du (jianhai.du@wvumedicine.org).

Materials Availability

Materials are available upon request from Dr. Jianhai Du.

Data and Code Availability

The *Nrl* mouse transcriptome datasets are available at NEI Commons: https://neicommons.nei.nih.gov/ #/dataDetail/442, https://neicommons.nei.nih.gov/#/dataDetail/445. All data used in this manuscript are available upon request from the lead author. No custom code was used in the analysis of the data.

METHODS

All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.101672.

ACKNOWLEDGMENTS

We thank Dr. Anand Swaroop and Dr. Zachary Batz from the National Eye Institute for sharing *Nrl* KO animals and their transcriptome datasets. We appreciate the comments from Dr. James Hurley from the University of Washington. We acknowledge the NSW lion tissue bank's support for this research. This work was supported by NIH Grants EY026030 (J.D.), EY029806 (W.L.), EY022645 (W.L.), the Retina Research Foundation (J.D.), the BrightFocus Foundation (J.D.), the Orphan Disease Center, University of Pennsylvania (MDBR-19-130-CRB1 W.L.), funds for Core facilities P20 GM103434 (WV INBRE grant), WVCTSI grant GM104942, funds from Australian NHMRC project grant (APP1145121 M.C.G.) and the Lowy Medical Research Institute. M.C.G. is a Sydney Medical School Fellow and supported by an Australian NHMRC practitioner fellowship.

AUTHOR CONTRIBUTIONS

Conceptualization, J.D.; Investigation, B.L., T.Z., W.L., Y.W., R.X., S. Zeng, R.Z., S. Zhu, L.Z.; Writing, B.L., T.Z., W.L., L.Z., M.C.G., and J.D.; Funding Acquisition, J.D.; Supervision, L.Z., M.C.G., and J.D.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: July 31, 2020 Revised: September 21, 2020 Accepted: October 8, 2020 Published: November 20, 2020

REFERENCES

Adijanto, J., Du, J., Moffat, C., Seifert, E.L., Hurle, J.B., and Philp, N.J. (2014). The retinal pigment epithelium utilizes fatty acids for ketogenesis. J. Biol. Chem. *289*, 20570–20582. Adler, L.t., Chen, C., and Koutalos, Y. (2014). Mitochondria contribute to NADPH generation in mouse rod photoreceptors. J. Biol. Chem. 289, 1519–1528. Bergersen, L.H. (2015). Lactate transport and signaling in the brain: potential therapeutic targets and roles in body-brain interaction. J. Cereb. Blood Flow Metab. 35, 176–185.



Bisbach, C.M., Hass, D.T., Robbings, B.M., Rountree, A.M., Sadilek, M., Sweet, I.R., and Hurley, J.B. (2020). Succinate can shuttle reducing power from the hypoxic retina to the O2-rich pigment epithelium. Cell Rep. *31*, 107606.

Brooks, M.J., Rajasimha, H.K., Roger, J.E., and Swaroop, A. (2011). Next-generation sequencing facilitates quantitative analysis of wild-type and Nrl(-/-) retinal transcriptomes. Mol. Vis. 17, 3034– 3054.

Brown, E.E., DeWeerd, A.J., Ildefonso, C.J., Lewin, A.S., and Ash, J.D. (2019). Mitochondrial oxidative stress in the retinal pigment epithelium (RPE) led to metabolic dysfunction in both the RPE and retinal photoreceptors. Redox Biol. 24, 101201.

Cappel, D.A., Deja, S., Duarte, J.A.G., Kucejova, B., Inigo, M., Fletcher, J.A., Fu, X., Berglund, E.D., Liu, T., Elmquist, J.K., et al. (2019). Pyruvatecarboxylase-Mediated anaplerosis promotes antioxidant capacity by sustaining TCA cycle and redox metabolism in liver. Cell Metab. 29, 1291– 1305.e8.

Casson, R.J., Wood, J.P., Han, G., Kittipassorn, T., Peet, D.J., and Chidlow, G. (2016). M-Type pyruvate kinase isoforms and lactate dehydrogenase A in the mammalian retina: metabolic implications. Invest. Ophthalmol. Vis. Sci. 57, 66–80.

Chao, J.R., Knight, K., Engel, A.L., Jankowski, C., Wang, Y., Manson, M.A., Gu, H., Djukovic, D., Raftery, D., Hurley, J.B., et al. (2017). Human retinal pigment epithelial cells prefer proline as a nutrient and transport metabolic intermediates to the retinal side. J. Biol. Chem. 292, 12895–12905.

Chen, B., Aredo, B., Ding, Y., Zhong, X., Zhu, Y., Zhao, C.X., Kumar, A., Xing, C., Gautron, L., Lyon, S., et al. (2020). Forward genetic analysis using OCT screening identifies Sfxn3 mutations leading to progressive outer retinal degeneration in mice. Proc. Natl. Acad. Sci. U S A 117, 12931–12942.

Chen, C., Blakeley, L.R., and Koutalos, Y. (2009). Formation of all-trans retinol after visual pigment bleaching in mouse photoreceptors. Invest. Ophthalmol. Vis. Sci. 50, 3589–3595.

Contreras, L., Ramirez, L., Du, J., Hurley, J.B., Satrustegui, J., and de la Villa, P. (2016). Deficient glucose and glutamine metabolism in Aralar/ AGC1/SIc25a12 knockout mice contributes to altered visual function. Mol. Vis. 22, 1198–1212.

Daniele, L.L., Lillo, C., Lyubarsky, A.L., Nikonov, S.S., Philp, N., Mears, A.J., Swaroop, A., Williams, D.S., and Pugh, E.N., Jr. (2005). Cone-like morphological, molecular, and electrophysiological features of the photoreceptors of the Nrl knockout mouse. Invest. Ophthalmol. Vis. Sci. 46, 2156–2167.

Dasarathy, J., Gruca, L.L., Bennett, C., Parimi, P.S., Duenas, C., Marczewski, S., Fierro, J.L., and Kalhan, S.C. (2010). Methionine metabolism in human pregnancy. Am. J. Clin. Nutr. *91*, 357–365.

Du, J., Cleghorn, W.M., Contreras, L., Lindsay, K., Rountree, A.M., Chertov, A.O., Turner, S.J., Sahaboglu, A., Linton, J., Sadilek, M., et al. (2013). Inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina. J. Biol. Chem. *288*, 36129–36140. Du, J., Yanagida, A., Knight, K., Engel, A.L., Vo, A.H., Jankowski, C., Sadilek, M., Tran, V.T., Manson, M.A., Ramakrishnan, A., et al. (2016). Reductive carboxylation is a major metabolic pathway in the retinal pigment epithelium. Proc. Natl. Acad. Sci. U S A *113*, 14710–14715.

Ferrington, D.A., Fisher, C.R., and Kowluru, R.A. (2020). Mitochondrial defects drive degenerative retinal diseases. Trends Mol. Med. 26, 105–118.

Fisher, C.R., and Ferrington, D.A. (2018). Perspective on AMD pathobiology: a bioenergetic crisis in the RPE. Invest. Ophthalmol. Vis. Sci. 59, AMD41–AMD47.

Futterman, S., and Kinoshita, J.H. (1959). Metabolism of the retina. I. Respiration of cattle retina. J. Biol. Chem. 234, 723–726.

Gamberino, W.C., Berkich, D.A., Lynch, C.J., Xu, B., and LaNoue, K.F. (1997). Role of pyruvate carboxylase in facilitation of synthesis of glutamate and glutamine in cultured astrocytes. J. Neurochem. *69*, 2312–2325.

Gantner, M.L., Eade, K., Wallace, M., Handzlik, M.K., Fallon, R., Trombley, J., Bonelli, R., Giles, S., Harkins-Perry, S., Heeren, T.F.C., et al. (2019). Serine and lipid metabolism in macular disease and peripheral neuropathy. N. Engl. J. Med. *381*, 1422–1433.

Grenell, A., Wang, Y., Yam, M., Swarup, A., Dilan, T.L., Hauer, A., Linton, J.D., Philp, N.J., Gregor, E., Zhu, S., et al. (2019). Loss of MPC1 reprograms retinal metabolism to impair visual function. Proc. Natl. Acad. Sci. U S A 116, 3530–3535.

Han, J.Y.S., Kinoshita, J., Bisetto, S., Bell, B.A., Nowak, R.A., Peachey, N.S., and Philp, N.J. (2020). Role of monocarboxylate transporters in regulating metabolic homeostasis in the outer retina: insight gained from cell-specific Bsg deletion. FASEB J. *34*, 5401–5419.

Harding, J.J., Hassett, P.C., Rixon, K.C., Bron, A.J., and Harvey, D.J. (1999). Sugars including erythronic and threonic acids in human aqueous humour. Curr. Eye Res. *19*, 131–136.

Hoang, Q.V., Linsenmeier, R.A., Chung, C.K., and Curcio, C.A. (2002). Photoreceptor inner segments in monkey and human retina: mitochondrial density, optics, and regional variation. Vis. Neurosci. *19*, 395–407.

Hui, S., Ghergurovich, J.M., Morscher, R.J., Jang, C., Teng, X., Lu, W., Esparza, L.A., Reya, T., Le, Z., Yanxiang Guo, J., et al. (2017). Glucose feeds the TCA cycle via circulating lactate. Nature *551*, 115–118.

Hurley, J.B., Lindsay, K.J., and Du, J. (2015). Glucose, lactate, and shuttling of metabolites in vertebrate retinas. J. Neurosci. Res. 93, 1079– 1092.

Jalil, M.A., Begum, L., Contreras, L., Pardo, B., lijima, M., Li, M.X., Ramos, M., Marmol, P., Horiuchi, M., Shimotsu, K., et al. (2005). Reduced N-acetylaspartate levels in mice lacking aralar, a brain- and muscle-type mitochondrial aspartateglutamate carrier. J. Biol. Chem. *280*, 31333– 31339.

Johnson, J.E., Jr., Perkins, G.A., Giddabasappa, A., Chaney, S., Xiao, W., White, A.D., Brown, J.M., Waggoner, J., Ellisman, M.H., and Fox, D.A. (2007). Spatiotemporal regulation of ATP and Ca2+ dynamics in vertebrate rod and cone ribbon synapses. Mol. Vis. *13*, 887–919.

iScience

Article

Jones, B.W., Pfeiffer, R.L., Ferrell, W.D., Watt, C.B., Tucker, J., and Marc, R.E. (2016). Retinal remodeling and metabolic alterations in human AMD. Front. Cell. Neurosci. *10*, 103.

Joyal, J.S., Gantner, M.L., and Smith, L.E.H. (2018). Retinal energy demands control vascular supply of the retina in development and disease: the role of neuronal lipid and glucose metabolism. Prog. Retin. Eye Res. 64, 131–156.

Kalloniatis, M., Marc, R.E., and Murry, R.F. (1996). Amino acid signatures in the primate retina. J. Neurosci. 16, 6807–6829.

Kanow, M.A., Giarmarco, M.M., Jankowski, C.S., Tsantilas, K., Engel, A.L., Du, J., Linton, J.D., Farnsworth, C.C., Sloat, S.R., Rountree, A., et al. (2017). Biochemical adaptations of the retina and retinal pigment epithelium support a metabolic ecosystem in the vertebrate eye. Elife *6*, e28899.

Kim, S., Lowe, A., Dharmat, R., Lee, S., Owen, L.A., Wang, J., Shakoor, A., Li, Y., Morgan, D.J., Hejazi, A.A., et al. (2019). Generation, transcriptome profiling, and functional validation of cone-rich human retinal organoids. Proc. Natl. Acad. Sci. U S A 116, 10824–10833.

Korenbrot, J.I. (2012). Speed, sensitivity, and stability of the light response in rod and cone photoreceptors: facts and models. Prog. Retin. Eye Res. 31, 442–466.

Kurihara, T., Westenskow, P.D., Gantner, M.L., Usui, Y., Schultz, A., Bravo, S., Aguilar, E., Wittgrove, C., Friedlander, M., Paris, L.P., et al. (2016). Hypoxia-induced metabolic stress in retinal pigment epithelial cells is sufficient to induce photoreceptor degeneration. Elife 5, e14319.

Leveillard, T., and Sahel, J.A. (2017). Metabolic and redox signaling in the retina. Cell. Mol. Life Sci. 74, 3649–3665.

Lieth, E., LaNoue, K.F., Berkich, D.A., Xu, B., Ratz, M., Taylor, C., and Hutson, S.M. (2001). Nitrogen shuttling between neurons and glial cells during glutamate synthesis. J. Neurochem. 76, 1712– 1723.

Lindsay, K.J., Du, J., Sloat, S.R., Contreras, L., Linton, J.D., Turner, S.J., Sadilek, M., Satrustegui, J., and Hurley, J.B. (2014). Pyruvate kinase and aspartate-glutamate carrier distributions reveal key metabolic links between neurons and glia in retina. Proc. Natl. Acad. Sci. U S A *111*, 15579– 15584.

Marc, R.E., Murry, R.F., and Basinger, S.F. (1995). Pattern recognition of amino acid signatures in retinal neurons. J. Neurosci. 15, 5106–5129.

Mears, A.J., Kondo, M., Swain, P.K., Takada, Y., Bush, R.A., Saunders, T.L., Sieving, P.A., and Swaroop, A. (2001). Nrl is required for rod photoreceptor development. Nat. Genet. *29*, 447–452.

Narayan, D.S., Chidlow, G., Wood, J.P., and Casson, R.J. (2017). Glucose metabolism in mammalian photoreceptor inner and outer segments. Clin. Exp. Ophthalmol. 45, 730–741.

iScience Article

Natoli, R., Rutar, M., Lu, Y.Z., Chu-Tan, J.A., Chen, Y., Saxena, K., Madigan, M., Valter, K., and Provis, J.M. (2016). The role of pyruvate in protecting 661W photoreceptor-like cells against lightinduced cell death. Curr. Eye Res. 41, 1473–1481.

Okawa, H., Sampath, A.P., Laughlin, S.B., and Fain, G.L. (2008). ATP consumption by mammalian rod photoreceptors in darkness and in light. Curr. Biol. *18*, 1917–1921.

Perkins, G.A., Ellisman, M.H., and Fox, D.A. (2003). Three-dimensional analysis of mouse rod and cone mitochondrial cristae architecture: bioenergetic and functional implications. Mol. Vis. 9, 60–73.

Perkins, G.A., Ellisman, M.H., and Fox, D.A. (2004). The structure-function correlates of mammalian rod and cone photoreceptor mitochondria: observations and unanswered questions. Mitochondrion 4, 695–703.

Petit, L., Ma, S., Cipi, J., Cheng, S.Y., Zieger, M., Hay, N., and Punzo, C. (2018). Aerobic glycolysis is essential for normal rod function and controls secondary cone death in retinitis pigmentosa. Cell Rep. 23, 2629–2642.

Rajala, A., Gupta, V.K., Anderson, R.E., and Rajala, R.V. (2013). Light activation of the insulin receptor regulates mitochondrial hexokinase. A possible mechanism of retinal neuroprotection. Mitochondrion 13, 566–576.

Ramos, M., Pardo, B., Llorente-Folch, I., Saheki, T., Del Arco, A., and Satrustegui, J. (2011). Deficiency of the mitochondrial transporter of aspartate/glutamate aralar/AGC1 causes hypomyelination and neuronal defects unrelated to myelin deficits in mouse brain. J. Neurosci. Res. *89*, 2008–2017.

Rashid, A., Bhatia, S.K., Mazzitello, K.I., Chrenek, M.A., Zhang, Q., Boatright, J.H., Grossniklaus, H.E., Jiang, Y., and Nickerson, J.M. (2016). RPE cell and sheet properties in normal and diseased eyes. Adv. Exp. Med. Biol. *854*, 757–763.

Ren, H., Liu, N.Y., Song, X.F., Ma, Y.S., and Zhai, X.Y. (2011). A novel specific application of pyruvate protects the mouse retina against white

light damage: differential stabilization of HIF-1alpha and HIF-2alpha. Invest. Ophthalmol. Vis. Sci. 52, 3112–3118.

Reyes-Reveles, J., Dhingra, A., Alexander, D., Bragin, A., Philp, N.J., and Boesze-Battaglia, K. (2017). Phagocytosis-dependent ketogenesis in retinal pigment epithelium. J. Biol. Chem. 292, 8038–8047.

Rueda, E.M., Johnson, J.E., Jr., Giddabasappa, A., Swaroop, A., Brooks, M.J., Sigel, I., Chaney, S.Y., and Fox, D.A. (2016). The cellular and compartmental profile of mouse retinal glycolysis, tricarboxylic acid cycle, oxidative phosphorylation, and ~P transferring kinases. Mol. Vis. 22, 847–885.

Ruzzo, E.K., Capo-Chichi, J.M., Ben-Zeev, B., Chitayat, D., Mao, H., Pappas, A.L., Hitomi, Y., Lu, Y.F., Yao, X., Hamdan, F.F., et al. (2013). Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalopathy. Neuron *80*, 429–441.

Sato, K., Mochida, S., Tomimoto, D., Konuma, T., Kiyota, N., Tsuda, S., Shiga, Y., Omodaka, K., and Nakazawa, T. (2020). A pyruvate dehydrogenase kinase inhibitor prevents retinal cell death and improves energy metabolism in rat retinas after ischemia/reperfusion injury. Exp. Eye Res. 193, 107997.

Sinha, T., Naash, M.I., and Al-Ubaidi, M.R. (2020). The symbiotic relationship between the neural retina and retinal pigment epithelium is supported by utilizing differential metabolic pathways. iScience 23, 101004.

Starnes, A.C., Huisingh, C., McGwin, G., Jr., Sloan, K.R., Ablonczy, Z., Smith, R.T., Curcio, C.A., and Ach, T. (2016). Multi-nucleate retinal pigment epithelium cells of the human macula exhibit a characteristic and highly specific distribution. Vis. Neurosci. 33, e001.

Taylor, M.R., Hurley, J.B., Van Epps, H.A., and Brockerhoff, S.E. (2004). A zebrafish model for pyruvate dehydrogenase deficiency: rescue of neurological dysfunction and embryonic lethality using a ketogenic diet. Proc. Natl. Acad. Sci. U S A 101, 4584–4589. Tserentsoodol, N., Sztein, J., Campos, M., Gordiyenko, N.V., Fariss, R.N., Lee, J.W., Fliesler, S.J., and Rodriguez, I.R. (2006). Uptake of cholesterol by the retina occurs primarily via a low density lipoprotein receptor-mediated process. Mol. Vis. *12*, 1306–1318.

Wang, W., Kini, A., Wang, Y., Liu, T., Chen, Y., Vukmanic, E., Emery, D., Liu, Y., Lu, X., Jin, L., et al. (2019). Metabolic deregulation of the bloodouter retinal barrier in retinitis pigmentosa. Cell Rep. 28, 1323–1334.e4.

Whitmore, S.S., Wagner, A.H., DeLuca, A.P., Drack, A.V., Stone, E.M., Tucker, B.A., Zeng, S., Braun, T.A., Mullins, R.F., and Scheetz, T.E. (2014). Transcriptomic analysis across nasal, temporal, and macular regions of human neural retina and RPE/choroid by RNA-Seq. Exp. Eye Res. *129*, 93–106.

Winkler, B.S., DeSantis, N., and Solomon, F. (1986). Multiple NADPH-producing pathways control glutathione (GSH) content in retina. Exp. Eye Res. 43, 829–847.

Xu, R., Ritz, B.K., Wang, Y., Huang, J., Zhao, C., Gong, K., Liu, X., and Du, J. (2020). The retina and retinal pigment epithelium differ in nitrogen metabolism and are metabolically connected. J. Biol. Chem. 295, 2324–2335.

Yam, M., Engel, A.L., Wang, Y., Zhu, S., Hauer, A., Zhang, R., Lohner, D., Huang, J., Dinterman, M., Zhao, C., et al. (2019). Proline mediates metabolic communication between retinal pigment epithelial cells and the retina. J. Biol. Chem. 294, 10278–10289.

Zeevalk, G.D., and Nicklas, W.J. (2000). Lactate prevents the alterations in tissue amino acids, decline in ATP, and cell damage due to aglycemia in retina. J. Neurochem. *75*, 1027– 1034.

Zhao, C., Yasumura, D., Li, X., Matthes, M., Lloyd, M., Nielsen, G., Ahern, K., Snyder, M., Bok, D., Dunaief, J.L., et al. (2011). mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice. J. Clin. Invest. *121*, 369–383.



iScience, Volume 23

Supplemental Information

Metabolic Features of Mouse

and Human Retinas: Rods versus Cones,

Macula versus Periphery, Retina versus RPE

Bo Li, Ting Zhang, Wei Liu, Yekai Wang, Rong Xu, Shaoxue Zeng, Rui Zhang, Siyan Zhu, Mark C. Gillies, Ling Zhu, and Jianhai Du

Supplemental Figures




Figure S1. Metabolic genes are temporally expressed in retinal organoids. Related to Figure 1. Differentially expressed genes along the time-course of human retinal organoids were intersected with the genes in metabolic pathways, resulting in a list of developmentally regulated metabolic genes. (A) Subgroups of developmentally regulated metabolic genes. (B-E) Heatmaps showing temporal expression of metabolic genes in (B) amino acid, (C) glycans & glycolysis, (D) ABC transporter & lipid and (E) nucleotide in human retinal organoids.

Top Small Molecule Transporters Ranked by WT Retinas (Substrate)




Figure S2. Top small molecule transporters ranked by WT retinas. Related to Figure 2. Top 20 most abundant small molecule transporters ranked by the expression in WT retinas.




Figure S3. Changed metabolic genes in the *Nrl* KO vs WT retinas. Related to Figure 2. (A) Number of changed genes in metabolic pathways in *Nrl* KO retinas. (B-E) Heatmaps of differentially expressed genes in (B) small molecule transport, (C) glycogen, pyruvate, TCA cycle & glycolysis, (D) amino acid, (E) lipid in *Nrl* KO retinas.





Figure S4. Metabolite uptake and release in human macular and peripheral retinas. Related to Figure 3. (A) Uptaked metabolites in the medium from peripheral retina culture. (B) Released metabolites in the medium from peripheral retina culture. (C) Released metabolites in the medium from macular retina culture. Error bars represent mean \pm SEM. N=8, **P*<0.05 vs baseline control. *t* test.



Top Small Molecule Transporters Ranked by Peripheral Retinas (Substrate)

Figure S5. Top small molecule transporters ranked by peripheral retinas. Related to Figure 3. Top 20 most abundant small molecule transporters ranked by the expression in human peripheral retinas. Periphery expression was the average of the expression in nasal and temporal regions.




Figure S6. Changed metabolic genes in the macular and peripheral retinas. Related to Figure 3. (A) Number of changed genes in metabolic pathways. (B-E) Heatmaps of differentially expressed genes in (B) small molecule transport, (C) glycans, (D) glycogen, pyruvate, TCA cycle & glycolysis, (E) amino acid, (F) fatty acid, mevalonate, cholesterol, ketone body & NAD metabolism.




Figure S7. Metabolite uptake and release in human macular and peripheral RPE/choroid. Related to Figure 4. (A) Uptaked metabolites in the medium from peripheral RPE/choroid culture. (B) Released metabolites in the medium from peripheral RPE/choroid culture. (C). Released metabolites in the medium from macular RPE/choroid culture. Error bars represent mean \pm SEM. N=8, **P*<0.05 vs baseline control. *t* test.

Top Small Molecule Transporters Ranked by Peripheral RPE/Choroid (Substrate)




Figure S8. Top small molecule transporters ranked by peripheral RPE/choroid. Related to Figure 4. Top 20 most abundant small molecule transporters ranked by the expression in human peripheral RPE/choroid. Periphery expression was the average of the expression in nasal and temporal regions.




Figure S9. Changed metabolic genes in the macular and peripheral RPE/choroid. Related to Figure 4. (A) Number of changed genes in metabolic pathways. (B-C) Heatmaps of differentially expressed genes in (B) glycolysis, TCA cycle & ETC, (C) small molecule transport, (D) ABC transporter & lipid.





Figure S10. Changed metabolic genes between human retinas and RPE/choroid. Related to Figure 5. (A) Number of changed genes in metabolic pathways in the macula. (B). Number of changed genes in metabolic pathways in the periphery.






Figure S11. The expression of TCA cycle genes in mouse and human retinas. Related to Figure 5-6.

Supplemental Tables

Donor ID	Eye (s)	Gender	Age	Post-mortem Delay	Known eye diseases
190800	both	F	66y	19h	No
190820	both	Μ	83y	28h	No
190850	both	F	77y	24h	No
190853	both	F	71y	28h	No

Table S5. Donor information for human retina and RPE/choroid explants. Related to Figure 3-4.

Table S6. Medium formulation for retinal organoid culture. Related to Figure 1.

0	Concentration			•	
Components	(mg/L)	mM	Category	Source	
Glycine	31.88	0.43	Amino Acids	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES + NEAA	
L-Alanine	11.12	0.12	Amino Acids	DMEM/F-12, HEPES + NEAA	
L-Alanyl-Glutamine (GlutaMAX)	431.00	1.99	Amino Acids	DMEM, high glucose, GlutaMAX™	
L-Arginine hydrochloride	115.75	0.55	Amino Acids	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
L-Asparagine	16.50	0.13	Amino Acids	DMEM/F-12, HEPES + NEAA	
L-Aspartic acid	16.63	0.13	Amino Acids	DMEM/F-12, HEPES + NEAA	
L-Cysteine hydrochloride-H2O	8.78	0.05	Amino Acids	DMEM/F-12, HEPES	
L-Cystine 2HCI	47.15	0.15	Amino Acids	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
L-Glutamic Acid	18.38	0.13	Amino Acids	DMEM/F-12, HEPES + NEAA	
L-Glutamine	182.50	1.25	Amino Acids	DMEM/F-12, HEPES	
L-Histidine hydrochloride-H2O	36.74	0.17	Amino Acids	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
L-Isoleucine	79.74	0.61	Amino Acids	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
L-Leucine	82.03	0.63	Amino Acids	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
L-Lysine hydrochloride	118.63	0.65	Amino Acids	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
L-Methionine	23.62	0.16	Amino Acids	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
L-Phenylalanine	50.74	0.31	Amino Acids	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
L-Proline	20.13	0.18	Amino Acids	DMEM/F-12, HEPES + NEAA	
L-Serine	44.63	0.43	Amino Acids	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES + NEAA	
L-Threonine	74.23	0.62	Amino Acids	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
L-Tryptophan	12.51	0.06	Amino Acids	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
L-Tyrosine disodium salt dihydrate	79.90	0.31	Amino Acids	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
L-Valine	73.43	0.63	Amino Acids	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
Biotin	1.75E-03	7.17E-06	Vitamins	DMEM/F-12, HEPES	
Choline chloride	6.49	0.05	Vitamins	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
D-Calcium pantothenate	3.12	0.01	Vitamins	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
Folic Acid	3.33	0.01	Vitamins	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
i-Inositol	9.90	0.06	Vitamins	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
Niacinamide	3.01	0.02	Vitamins	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	
Pyridoxal hydrochloride	2.00	0.01	Vitamins	DMEM, high glucose, GlutaMAX™	
Pyridoxine hydrochloride	1.00	4.85E-03	Vitamins	DMEM/F-12, HEPES	
Riboflavin	0.31	8.23E-04	Vitamins	DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES	

Thiamine hydrochloride 3.09 0.01 Vitamins DME//F-12, HEPES Vitamine 12 0.34 2.51E-04 Vitamins DME//F-12, HEPES Calcium Chloride (CaCl2) (anhyd.) 158.30 1.43 Satts DME//F-12, HEPES Cupric suffact (CuS04- 5H2O) 6.50E-04 2.60E-06 Satts DME//F-12, HEPES Ferric Nitrate (Fer(NO3)3*9H2O) 0.08 1.86E-04 Satts DME//F-12, HEPES Ferric Nitrate (fer(NO3)3*9H2O) 0.21 7.50E-04 Satts DME//F-12, HEPES Magnesium Chloride (anhydrou) 14.32 0.15 Satts DME//F-12, HEPES Magnesium Suffate (CM)SO4 (anhyd.) 73.26 0.61 Satts DME//F-12, HEPES Magnesium Chloride (MgSO4) (anhyd.) 73.26 0.61 Satts DME//F-12, HEPES Magnesium Chloride (MgSO4) (anhyd.) 73.26 0.61 Satts DME//F-12, HEPES VMGSO4 (anhyd.) 73.26 0.61 Satts DME//F-12, HEPES Sodium Bicarbonate (NG1) 10.75 Satts DME//F-12, HEPES Satts Sod					DMEM, high glucose, GlutaMAX™ +
Calcium Chloride (CaCi2) (anhyd.) 158.30 1.43 Satts DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES CaCi2) (anhyd.) 6.50E-04 2.60E-06 Satts DMEM/F-12, HEPES Ferric Nitrate (Fer(NO3)3*9H2O) 0.08 1.66E-04 Satts DMEM/F-12, HEPES Ferrous Suffate (FFSO4 Inorganic (MgSO4) (anhyd.) 7.50E-04 Satts DMEM/F-12, HEPES Magnesium Chloride (anhydrous) 14.32 0.15 Satts DMEM/F-12, HEPES Magnesium Chloride (MgSO4) (anhyd.) 73.26 0.61 Satts DMEM/F-12, HEPES Magnesium Chloride (MgSO4) (anhyd.) 73.26 0.61 Satts DMEM/F-12, HEPES Potassium Chloride (MgSO4) (anhyd.) 73.26 0.75 Satts DMEM/F-12, HEPES Sodium Bicarbonate (NaHCO3) 2450.00 29.17 Satts DMEM/F-12, HEPES Sodium Chloride (NaCI) 6697.75 115.48 Satts DMEM/F-12, HEPES Sodium Phosphate dibasic (Na2PPO4) 0.25 Satts DMEM/F-12, HEPES Sodium Phosphate monobasic (Na12PO4- 90.27 0.26 Satts DMEM/F-12, HEPES<	Thiamine hydrochloride	3.09	0.01	Vitamins	DMEM/F-12, HEPES
(CaC2) (anhyd.) 158.30 1.43 Satis DMEM/F-12, HEPES Cupric sulfate (CuSO4- SH2O) 6.50E-04 2.60E-06 Satis DMEM/F-12, HEPES Ferric Nitrate Inorganic DMEM/F-12, HEPES DMEM/F-12, HEPES Ferric Nitrate 0.08 1.86E-04 Satis DMEM/F-12, HEPES Ferrous Sulfate (FeSO4 0.15 Satis DMEM/F-12, HEPES Magnesium Sulfate 0.21 7.50E-04 Satis DMEM/F-12, HEPES Magnesium Sulfate 0.21 Satis DMEM/F-12, HEPES Inorganic Magnesium Sulfate 14.32 0.15 Satis DMEM/F-12, HEPES Potassium Chloride Inorganic DMEM/F-12, HEPES Inorganic Norganic Inorganic DMEM/F-12, HEPES Inorganic Sodium Chloride (NaCI) 6697.75 115.48 Satis DMEM/F-12, HEPES Sodium Phosphate Inorganic Inorganic Inorganic Inorganic Sodium Phosphate Inorganic Inorganic Inorganic Inorganic Inorganic <		0.34	2.51E-04		
Cupric sulfate (CuSO4- SH2O) 6.50E-04 2.60E-06 Salts DMEM/F-12, HEPES Ferric Nitrate (Fer(NO3)379H2O) 0.08 1.86E-04 Salts DMEM/F-12, HEPES Ferrous Sulfate (FeSO4 0.21 7.50E-04 Salts DMEM/F-12, HEPES Magnesium Chloride (antydrous) 14.32 0.15 Salts DMEM/F-12, HEPES Magnesium Sulfate (MgSO4) (antyd.) 73.26 0.61 Salts DMEM/F-12, HEPES Magnesium Chloride (antydrous) 14.32 0.15 Salts DMEM/F-12, HEPES Magnesium Chloride (MgSO4) (antyd.) 73.26 0.61 Salts DMEM/F-12, HEPES Potassium Chloride (NGCI) 355.90 4.75 Salts DMEM/F-12, HEPES Sodium Bicarbonate (NaHCO3) 2450.00 29.17 Salts DMEM/F-12, HEPES Sodium Phosphate dibasic (Na2HPO4) 1norganic antydrous Merganic antydrous DMEM/F-12, HEPES DMEM/F-12, HEPES Sodium Phosphate dibasic (Na2HPO4) 35.51 0.25 Salts DMEM/F-12, HEPES Sodium Phosphate dibasic (Na2HPO4) 35.51 0.25 Salts					
5H2O) 6.50E-04 2.60E-06 Satis DMEM/F-12, HEPES Ferrio Nitrate (Fe(NO3)3'9H2O) 0.08 1.86E-04 Inorganic Inorganic DMEM/F-12, HEPES Ferrous Sulfate (FeSO4 (anhydrous) 1.86E-04 Satis DMEM/F-12, HEPES Magnesium Chloride (anhydrous) 14.32 0.15 Satis DMEM/F-12, HEPES Magnesium Sulfate (MgSO4) (anhyd.) 73.26 0.61 Satis DMEM/F-12, HEPES Potassium Chloride (CI) 355.90 4.75 Satis DMEM/F-12, HEPES Sodium Bicarbonate (NAHCO3) 2450.00 29.17 Satis DMEM/F-12, HEPES Sodium Phosphate dibasic (Na2HPO4) 6697.75 115.48 Satis DMEM/F-12, HEPES Sodium Phosphate dibasic (Na2HPO4) 635.51 0.25 Satis DMEM/F-12, HEPES Sodium Phosphate monobasic (NaH2PO4- H2O) 93.75 0.68 Satis DMEM/F-12, HEPES Other Magnesic 0MEM/F-12, HEPES DMEM/F-12, HEPES DMEM/F-12, HEPES Clocase (Dextrose) 382.55 0.25 Satis DMEM/F-12, HEPES <t< td=""><td></td><td>158.30</td><td>1.43</td><td></td><td>DMEM/F-12, HEPES</td></t<>		158.30	1.43		DMEM/F-12, HEPES
Ferric Nitrate (Fe(NO3)3*9H2O) Inorganic 0.08 Inorganic 1.86E-04 DMEM, High quicose, GlutaMAX™ + DMEM/F-12, HEPES Ferrous Sulfate (FeSO4 7H2O) 0.21 7.50E-04 Satts DMEM/F-12, HEPES Magnesium Chloride (an)ydrous) 14.32 0.15 Satts DMEM/F-12, HEPES Magnesium Sulfate (myS04) (anhyd.) 73.26 0.61 Satts DMEM/F-12, HEPES Potassium Chloride (MSC4) (anhyd.) 73.26 0.61 Satts DMEM/F-12, HEPES Sodium Bicarbonate (NaHCO3) 2450.00 29.17 Satts DMEM/F-12, HEPES Sodium Chloride (NaCl) 6697.75 115.48 Satts DMEM/F-12, HEPES Sodium Phosphate monobasic (Na2HPO4) 1norganic DMEM/F-12, HEPES DMEM/F-12, HEPES Sodium Phosphate monobasic (Na2HPO4) 1soff astts DMEM/F-12, HEPES DMEM/F-12, HEPES Sodium Phosphate monobasic (Na2HPO4) 1soff astts DMEM/F-12, HEPES DMEM/F-12, HEPES Sodium Phosphate monobasic (Na4H2PO4- H2O) 0.22 7.50E-04 Satts DMEM/F-12, HEPES Sodium Phosphate monobasic (Na4H2PO4- H2O) 0.22 7.50E-05 DM		6 50E 04			DMEM/E 12 HEDES
(Fe(NO3)3"9H2O) 0.08 1.86E-04 Salts DMEM/F-12, HEPES Ferrous Sulfate (FeSO4 0.21 7.50E-04 Salts DMEM/F-12, HEPES Magnesium Chloride (anhydrous) 14.32 0.15 Salts DMEM/F-12, HEPES Magnesium Sulfate (MgSO4) (anhyd.) 73.26 0.61 Salts DMEM/F-12, HEPES Potassium Chloride (MgSO4) (anhyd.) 73.26 0.61 Salts DMEM/F-12, HEPES Potassium Chloride (MgSO4) (anhyd.) 73.26 0.61 Salts DMEM/F-12, HEPES Sodium Blcarbonate (NaHCO3) 2450.00 29.17 Salts DMEM/F-12, HEPES Sodium Chloride (NaCl) 6697.75 115.48 Salts DMEM/F-12, HEPES Sodium Phosphate dibasic (Na2HPO4) 1 Inorganic DMEM/F-12, HEPES Sodium Phosphate monobasic (NaH2PO4+ 1 Inorganic DMEM/F-12, HEPES Zinc sulfate (ZnSO4- 7.50E-04 Salts DMEM/F-12, HEPES Zinc sulfate (ZnSO4- 7.50E-04 Salts DMEM/F-12, HEPES D-Glucose (Dextrose) 3825.50 21.25 Compone	/	0.30E-04	2.00E-00		
Ferrous Sulfate (FeSO4 7H2Q) norganic Inorganic Inorganic 7H2Q) 0.21 7.50E-04 Satts DMEM/F-12, HEPES Magnesium Chloride (anhydrous) 14.32 0.15 Satts DMEM/F-12, HEPES Magnesium Sulfate (MgSO4) (anhyd.) 73.26 0.61 Satts DMEM/F-12, HEPES Potassium Chloride (KCI) 355.90 4.75 Satts DMEM/F-12, HEPES Sodium Bicarbonate (NaHCO3) 2450.00 29.17 Satts DMEM/F-12, HEPES Sodium Chloride (NaCI) 6697.75 115.48 Satts DMEM/F-12, HEPES Sodium Phosphate monobasic (Na2HPO4) 6697.75 115.48 Satts DMEM/F-12, HEPES Sodium Phosphate monobasic (Na2HPO4) 10.75 Satts DMEM/F-12, HEPES DMEM/F-12, HEPES Sodium Phosphate monobasic (Na2HPO4- H2O) 93.75 0.68 Satts DMEM/F-12, HEPES Sodium Phosphate monobasic (Na2HPO4- H2O) 0.22 7.50E-04 Satts DMEM/F-12, HEPES Sodium Phosphate monobasic (Na2HPO4- H2O) 0.22 7.50E-04 Satts DMEM/F-12, HEPES		0.08	1.86E-04		
Magnesium Chloride (anhydrous) Inorganic 14.32 Inorganic 0.15 DMEM/F-12, HEPES Magnesium Sulfate (MgSO4) (anhyd.) 73.26 0.61 Salts DMEM, high glucose, GlutaMAX™ + 0MEM/F-12, HEPES Potassium Chloride (KCI) 355.90 4.75 Salts DMEM, high glucose, GlutaMAX™ + 0MEM/F-12, HEPES Sodium Bicarbonate (NaHCO3) 2450.00 29.17 Salts DMEM/F-12, HEPES Sodium Chloride (NaCI) 6697.75 115.48 Salts DMEM/F-12, HEPES Sodium Phosphate dibasic (Na2HPO4) anhydrous 35.51 0.25 Salts DMEM/F-12, HEPES Sodium Phosphate monobasic (NaH2PO4) anhydrous 35.51 0.25 Salts DMEM/F-12, HEPES Sodium Phosphate monobasic (NaH2PO4- H2O) 93.75 0.68 Salts DMEM/F-12, HEPES Zinc sulfate (ZnSO4- 712O) 0.22 7.50E-04 DMEM/F-12, HEPES MEM/F-12, HEPES JLinc sulfate (ZnSO4- 712O) 0.22 7.50E-04 DMEM/F-12, HEPES MEM/F-12, HEPES HEPES 1787.25 7.51 Components DMEM/F-12, HEPES MEM/F-12, HEPES H2O) 0.22					
(anf)vdrous) 14.32 0.15 Salts DMEM/F-12, HEPES Magnesium Sulfate (MgSO4) (anhyd.) 73.26 0.61 Salts DMEM/F-12, HEPES Potassium Chloride (KCI) 355.90 4.75 Salts DMEM/F-12, HEPES Sodium Bicarbonate (NAECO3) 2450.00 29.17 Salts DMEM/F-12, HEPES Sodium Chloride (NaCI) 6697.75 115.48 Salts DMEM/F-12, HEPES Sodium Phosphate dibasic (Na2HPO4) Inorganic DMEM/F-12, HEPES Inorganic Sodium Phosphate monobasic (Na2HPO4) 35.51 0.25 Salts DMEM/F-12, HEPES Sodium Phosphate monobasic (Na2HPO4) 10.75 0.0.25 Salts DMEM/F-12, HEPES Sodium Phosphate monobasic (Na2HPO4) 35.51 0.25 Salts DMEM/F-12, HEPES Zinc sulfate (ZnSO4- 0.22 7.50E-04 Salts DMEM/F-12, HEPES D-Glucose (Dextrose) 3825.50 21.25 Components DMEM/F-12, HEPES HEPES 1787.25 7.51 Components DMEM/F-12, HEPES HEPES 1787.25 <td></td> <td>0.21</td> <td>7.50E-04</td> <td></td> <td>DMEM/F-12, HEPES</td>		0.21	7.50E-04		DMEM/F-12, HEPES
Magnesium Sulfate (MgSQ4) (anhyd.) 73.26 Inorganic Salts DMEM/F-12, HEPES GlutaMAX™ + DMEM/F-12, HEPES Potassium Chloride (KCI) 355.90 4.75 Salts DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES Sodium Bicarbonate (KAICO3) 2450.00 29.17 Salts DMEM, high glucose, GlutaMAX™ + Sodium Chloride (NaCI) 6697.75 115.48 Salts DMEM/F-12, HEPES Sodium Chloride (NaCI) 6697.75 115.48 Salts DMEM/F-12, HEPES Sodium Phosphate dibasic (Na2HPO4) anhydrous 35.51 0.25 Salts DMEM/F-12, HEPES Sodium Phosphate monobasic (NaH2PO4- H2O) 93.75 0.68 Salts DMEM/F-12, HEPES Zinc sulfate (ZnSO4- 7H2O) 0.22 7.50E-04 Salts DMEM/F-12, HEPES Other 0Her DMEM/F-12, HEPES DMEM/F-12, HEPES Max * + D-Glucose (Dextrose) 3825.50 21.25 Components DMEM/F-12, HEPES HEPES 1787.25 7.51 Components DMEM/F-12, HEPES Hupoxanthine Na 1.20 0.01 Components					
(MgSO4) (anhyd.) 73.26 0.61 Salts DMEM/F-12, HEPES Potassium Chloride (KCI) 355.90 4.75 Salts DMEM/F-12, HEPES Sodium Bicarbonate (NaHCO3) 2450.00 29.17 Salts DMEM/F-12, HEPES Sodium Chloride (NaCI) 6697.75 115.48 Salts DMEM/F-12, HEPES Sodium Phosphate dibasic (Na2HPO4) Inorganic DMEM/F-12, HEPES DMEM/F-12, HEPES Sodium Phosphate monobasic (NaH2PO4- H2O) 15.51 0.25 Salts DMEM/F-12, HEPES Sodium Phosphate monobasic (NaH2PO4- H2O) 35.51 0.25 Salts DMEM/F-12, HEPES Zinc sulfate (ZnSO4- TH2O) 93.75 0.68 Salts DMEM/F-12, HEPES Po-Glucose (Dextrose) 3825.50 21.25 Omponents DMEM/F-12, HEPES Other 0ther DMEM/F-12, HEPES DMEM/F-12, HEPES Po-Glucose (Dextrose) 3825.50 21.25 Components DMEM/F-12, HEPES Other 0ther DMEM/F-12, HEPES DMEM/F-12, HEPES Lipoic Acid 0.02 7.50E-05		14.32	0.15		
Pofassium Chloride (KCI) Inorganic 355.90 Inorganic 4.75 Inorganic Salts Inorganic DMEM/F-12, HEPES ClutaMAX™ + DMEM/F-12, HEPES Sodium Bicarbonate (NaHCO3) 2450.00 29.17 Salts DMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPES Sodium Chloride (NaCl) 6697.75 115.48 Salts DMEM/F-12, HEPES Sodium Phosphate dibasic (Na2HPO4) anhydrous 35.51 0.25 Salts DMEM/F-12, HEPES Sodium Phosphate dibasic (Na2HPO4- H2O) 35.51 0.25 Salts DMEM/F-12, HEPES Sodium Phosphate dibasic (Na2HPO4- H2O) 93.75 0.68 Salts DMEM/F-12, HEPES Solium Phosphate dibasic (NaH2PO4- H2O) 0.22 7.50E-04 Salts DMEM/F-12, HEPES D-Glucose (Dextrose) 3825.50 21.25 Components DMEM/F-12, HEPES D-Glucose (Dextrose) 3825.50 21.25 Components DMEM/F-12, HEPES HEPES 1787.25 7.51 Components DMEM/F-12, HEPES Upoic Acid 0.02 7.50E-05 Components DMEM/F-12, HEPES Upoic Acid 0.02		72.26	0.61		
(KCl) 355.90 4.75 Salts DMEM/F-12, HEPES Sodium Bicarbonate (NaHCO3) 2450.00 29.17 Salts DMEM/F-12, HEPES Sodium Chloride (NaCl) 6697.75 115.48 Salts DMEM/F-12, HEPES Sodium Phosphate dibasic (Na2HPO4) anhydrous 35.51 0.25 Salts DMEM/F-12, HEPES Sodium Phosphate monobasic (NaH2PO4- 1400) 35.51 0.25 Salts DMEM/F-12, HEPES Sodium Phosphate monobasic (NaH2PO4- H2O) 93.75 0.68 Salts DMEM/F-12, HEPES Zinc sulfate (ZnSO4- 7H2O) 93.75 0.68 Salts DMEM/F-12, HEPES D-Glucose (Dextrose) 3825.50 21.25 Components DMEM/F-12, HEPES D-Glucose (Dextrose) 3825.50 21.25 Components DMEM/F-12, HEPES HEPES 1787.25 7.51 Components DMEM/F-12, HEPES Linoleic Acid 0.02 7.50E-04 Components DMEM/F-12, HEPES Linoleic Acid 0.02 7.50E-05 Components DMEM/F-12, HEPES Linoleic Acid <t< td=""><td></td><td>75.20</td><td>0.01</td><td></td><td></td></t<>		75.20	0.01		
Sodium Bicarbonate (NaHCO3)2450.0029.17Inorganic SaltsDMEM, high glucose, GlutaMAXTM + DMEM/F-12, HEPESSodium Chloride (NaCl)6697.75115.48SaltsDMEM/F-12, HEPESSodium Phosphate dibasic (Na2HPO4) anhydrous35.510.25SaltsDMEM/F-12, HEPESSodium Phosphate monobasic (NaH2PO4- H2O)35.510.25SaltsDMEM/F-12, HEPESSodium Phosphate monobasic (NaH2PO4- H2O)93.750.68SaltsDMEM/F-12, HEPESSolius Sulfate (ZnSO4- 7H2O)7.50E-04SaltsDMEM/F-12, HEPESZinc sulfate (ZnSO4- 7H2O)0.227.50E-04SaltsDMEM/F-12, HEPESOther D-Glucose (Dextrose)3825.5021.25ComponentsDMEM/F-12, HEPESHEPES1787.257.51ComponentsDMEM/F-12, HEPESHypoxanthine Na1.200.01ComponentsDMEM/F-12, HEPESLipoic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESUptor Acid0.052.55E-04ComponentsDMEM/F-12, HEPESUptor Acid0.052.55E-04ComponentsDMEM/F-12, HEPESUptor Acid0.052.55E-04ComponentsDMEM/F-12, HEPESUptor Acid0.052.55E-04ComponentsDMEM/F-12, HEPESOther Putrescine 2HCl0.042.52E-04ComponentsDMEM		355.90	4.75		
(NaHCO3)2450.0029.17SaltsDMEM/F-12, HEPESSodium Chloride (NaCl)6697.75115.48SaltsDMEM, high glucose, GlutaMAX™ +Sodium PhosphateInorganicInorganicDMEM/F-12, HEPESSodium Phosphate10.5SaltsDMEM/F-12, HEPESSodium Phosphate10.5SaltsDMEM/F-12, HEPESSodium Phosphate10.07ganicDMEM/F-12, HEPESSodium Phosphate10.07ganicDMEM/F-12, HEPESSodium Phosphate10.07ganicDMEM/F-12, HEPESSodium Phosphate10.07ganicDMEM/F-12, HEPESSodium Phosphate0.227.50E-04SaltsDMEM/F-12, HEPES0.227.50E-04SaltsZinc sulfate (ZnSO4-0.227.50E-04DMEM/F-12, HEPESZinc sulfate (ZnSO4-0.12OtherDMEM/F-12, HEPESP-Glucose (Dextrose)3825.5021.25ComponentsDMEM/F-12, HEPESHEPES1787.257.51ComponentsDMEM/F-12, HEPESHEPES0.01ComponentsDMEM/F-12, HEPESHypoxanthine Na1.200.01ComponentsDMEM/F-12, HEPESLipoic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLipoic Acid0.032.55E-04ComponentsDMEM/F-12, HEPESPuterscine 2HCI0.042.52E-04ComponentsDMEM/F-12, HEPESOther0ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESSodium					
Sodium Chloride (NaCl)6697.75115.48SaltsDMEM/F-12, HEPESSodium Phosphate dibasic (Na2HPO4) anhydrous35.510.25SaltsDMEM/F-12, HEPESSodium Phosphate monobasic (NaH2PO4- H2O)93.750.68SaltsDMEM/F-12, HEPESZinc sulfate (ZnSO4- TH2O)0.227.50E-04SaltsDMEM/F-12, HEPESZinc sulfate (ZnSO4- TH2O)0.227.50E-04SaltsDMEM/F-12, HEPESD-Glucose (Dextrose)3825.5021.25DMEM/F-12, HEPESHEPES1787.257.51ComponentsDMEM/F-12, HEPESHEPES1787.257.51OtherDMEM/F-12, HEPESLinoleic Acid0.027.50E-04ComponentsDMEM/F-12, HEPESLinoleic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCI0.042.52E-04ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPES	(NaHCO3)	2450.00	29.17		
Sodium Phosphate dibasic (Na2HPO4) anhydrous35.510.25Inorganic SaltsDMEM/F-12, HEPESSodium Phosphate monobasic (NaH2PO4- H2O)93.750.68DMEM/F-12, HEPESZinc sulfate (ZnSO4- 7H2O)0.227.50E-04SaltsDMEM/F-12, HEPESOther D-Glucose (Dextrose)3825.5021.25ComponentsDMEM/F-12, HEPESD-Glucose (Dextrose)3825.5021.25ComponentsDMEM/F-12, HEPESHEPES1787.257.51ComponentsDMEM/F-12, HEPESHypoxanthine Na1.200.01ComponentsDMEM/F-12, HEPESLinoleic Acid0.027.50E-04ComponentsDMEM/F-12, HEPESUpic Acid0.027.50E-04ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESOther Upic Acid0.042.52E-04ComponentsDMEM/F-12, HEPESOther Upic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESOther Upic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESOther Upic Acid0.052.52E-04ComponentsDMEM/F-12, HEPESOther Dother0.042.52E-04ComponentsDMEM/F-12, HEPESOther Other0.05ComponentsDMEM/F-12, HEPESOther Other0.050.25ComponentsDMEM/F-12, HEPESOther Other0.050.05ComponentsDMEM/F-12, HEPESOther Other0.050.05Compone					
dibasic (Na2HPO4) anhydrous35.51Inorganic SaltsDMEM/F-12, HEPESSodium Phosphate monobasic (NaH2PO4- H2O)93.750.68SaltsDMEM/F-12, HEPESZinc sulfate (ZnSO4- 7H2O)0.227.50E-04SaltsDMEM/F-12, HEPESZinc sulfate (ZnSO4- 7H2O)0.227.50E-04SaltsDMEM/F-12, HEPESD-Glucose (Dextrose)3825.5021.25ComponentsDMEM/F-12, HEPESHEPES1787.257.51ComponentsDMEM/F-12, HEPESHepes0.01ComponentsDMEM/F-12, HEPESHiposanthine Na1.200.01ComponentsDMEM/F-12, HEPESLipoic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCl0.042.52E-04ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESTaurine11.550.03ComponentsDMEM/F-12, HEPESTaurine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementSupplement60X), serum free1XInoSupplementSupplement		6697.75	115.48	Salts	DMEM/F-12, HEPES
anhydrous35.510.25SaltsDMEM/F-12, HEPESSodium Phosphate monobasic (NaH2PO4- H2O)93.750.68SaltsDMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPESZinc sulfate (ZnSO4- 7H2O)0.227.50E-04SaltsDMEM/F-12, HEPESD-Glucose (Dextrose)3825.5021.25ComponentsDMEM/F-12, HEPESD-Glucose (Dextrose)3825.5021.25ComponentsDMEM/F-12, HEPESHEPES1787.257.51ComponentsDMEM/F-12, HEPESHypoxanthine Na1.200.01ComponentsDMEM/F-12, HEPESLinoleic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESUpoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCl0.042.52E-04ComponentsDMEM/F-12, HEPESOther0.01ComponentsDMEM/F-12, HEPESOther0.01ComponentsDMEM/F-12, HEPESPutrescine 2HCl0.042.52E-04ComponentsOther0.05ComponentsDMEM/F-12, HEPESOther0.050.25ComponentsDMEM/F-12, HEPESTaurine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10Supplement60X), serum free1XVSupplement					
Sodium Phosphate monobasic (NaH2PO4- H2O)93.750.68Inorganic SaitsDMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPESZinc sulfate (ZnSO4- 7H2O)0.227.50E-04SaitsDMEM/F-12, HEPESD-Glucose (Dextrose)3825.5021.25OtherDMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPESD-Glucose (Dextrose)3825.5021.25ComponentsDMEM/F-12, HEPESHEPES1787.257.51ComponentsDMEM/F-12, HEPESHypoxanthine Na1.200.01ComponentsDMEM/F-12, HEPESLinoleic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCl0.042.52E-04ComponentsDMEM/F-12, HEPESOther Components0.25OtherDMEM/F-12, HEPESOther Components0.042.52E-04ComponentsOther Components0.042.52E-04OtherOther Components0.25ComponentsDMEM/F-12, HEPESOther Components0.25OtherDMEM/F-12, HEPESPutrescine 2HCl0.042.52E-04ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04ComponentsDMEM/F-12, HEPESThymidine12.520.10SupplementSupplementGottar12.520.10SupplementGother ComponentsDMEM/F-12, HEPES<		25 51	0.25		DMEM/E 12 HEDES
monobasic (NaH2PO4- H2O)93.75InorganicDMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPESZinc sulfate (ZnSO4- 7H2O)0.227.50E-04SaltsDMEM/F-12, HEPES7H2O)0.227.50E-04SaltsDMEM/F-12, HEPESD-Glucose (Dextrose)3825.5021.25ComponentsDMEM/F-12, HEPESHEPES1787.257.51ComponentsDMEM/F-12, HEPESHEPES1787.257.51ComponentsDMEM/F-12, HEPESHupoxanthine Na1.200.01ComponentsDMEM/F-12, HEPESLinoleic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLinoleic Acid0.027.50E-04CotherDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCl0.042.52E-04ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementSupplement60X), serum free1XIASupplementSupplement		30.01	0.25	Sails	DNEM/F-12, HEFES
H2O)93.750.68SaltsDMEM/F-12, HEPESZinc sulfate (ZnSO4- 7H2O)0.227.50E-04SaltsDMEM/F-12, HEPESD-Glucose (Dextrose)3825.5021.25ComponentsDMEM/F-12, HEPESD-Glucose (Dextrose)3825.5021.25ComponentsDMEM/F-12, HEPESHEPES1787.257.51ComponentsDMEM/F-12, HEPESHypoxanthine Na1.200.01ComponentsDMEM/F-12, HEPESLinoleic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLipoic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCI0.042.52E-04ComponentsDMEM/F-12, HEPESOther0ther0ther0ther0therSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementSupplement(50X), serum free1XSupplementSupplement				Inorganic	DMEM high glucose. GlutaMAX™ +
Zinc sulfate (ZnSO4- 7H2O)0.22Inorganic 7.50E-04Inorganic SaltsDMEM/F-12, HEPESD-Glucose (Dextrose)3825.5021.25ComponentsDMEM/F-12, HEPESD-Glucose (Dextrose)3825.5021.25ComponentsDMEM/F-12, HEPESHEPES1787.257.51ComponentsDMEM/F-12, HEPESHypoxanthine Na1.200.01ComponentsDMEM/F-12, HEPESLinoleic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLipoic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCI0.042.52E-04ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10Supplement60Xher0.25ZE-04SupplementSupplement50X), serum free1X-Supplement		93.75	0.68		
7H2O)0.227.50E-04SaltsDMEM/F-12, HEPESD-Glucose (Dextrose)3825.5021.25ComponentsDMEM/F-12, HEPES3825.5021.25ComponentsDMEM/F-12, HEPESHEPES1787.257.51ComponentsDMEM/F-12, HEPESHypoxanthine Na1.200.01ComponentsDMEM/F-12, HEPESLinoleic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLinoleic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCl0.042.52E-04ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESTaurine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementB-27™ Supplement (50X), serum free1XIASupplement	/				
D-Glucose (Dextrose)3825.5021.25ComponentsDMEM/F-12, HEPESHEPES1787.257.51ComponentsDMEM/F-12, HEPESHypoxanthine Na1.200.01ComponentsDMEM/F-12, HEPESLinoleic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLipoic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCI0.042.52E-04ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementSupplementB-27™ Supplement (50X), serum free1XIISupplement	7H2O)	0.22	7.50E-04		
HEPES1787.25Other ComponentsDMEM/F-12, HEPESHypoxanthine Na1.200.01ComponentsDMEM/F-12, HEPESLinoleic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCl0.042.52E-04ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementB-27™ Supplement (50X), serum free1XSupplementSupplement					
HEPES1787.257.51ComponentsDMEM/F-12, HEPESHypoxanthine Na1.200.01ComponentsDMEM/F-12, HEPESLinoleic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCl0.042.52E-04ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementSupplement60X), serum free1XIASupplementSupplement	D-Glucose (Dextrose)	3825.50	21.25		DMEM/F-12, HEPES
Hypoxanthine Na1.20Other ComponentsDMEM/F-12, HEPESLinoleic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCl0.042.52E-04ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementSupplement(50X), serum free1XIASupplementSupplement		1707.05	7 5 1		
Hypoxanthine Na1.200.01ComponentsDMEM/F-12, HEPESLinoleic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCI0.042.52E-04ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementSupplement(50X), serum free1XIASupplementSupplement	HEPES	1707.25	1.51		
Linoleic Acid0.027.50E-05Other ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCl0.042.52E-04ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementB-27™ Supplement (50X), serum free1XImage: SupplementSupplement	Hypoxanthine Na	1 20	0.01		DMEM/E-12 HEPES
Linoleic Acid0.027.50E-05ComponentsDMEM/F-12, HEPESLipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCI0.042.52E-04ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04ComponentsDMEM/F-12, HEPESB-27™ Supplement (50X), serum free1XIAIA		1.20	0.01		
Lipoic Acid0.052.55E-04ComponentsDMEM/F-12, HEPESPhenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCl0.042.52E-04ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementB-27 ™ Supplement1XImage: SupplementSupplement(50X), serum free1XImage: SupplementSupplement	Linoleic Acid	0.02	7.50E-05		DMEM/F-12, HEPES
Phenol Red11.550.03Other ComponentsDMEM, high glucose, GlutaMAX™ + DMEM/F-12, HEPESPutrescine 2HCl0.042.52E-04Other ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementB-27™ Supplement (50X), serum free1XImage: Component (Supplement)Supplement)				Other	
Phenol Red11.550.03ComponentsDMEM/F-12, HEPESPutrescine 2HCl0.042.52E-04OtherDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04OtherDMEM/F-12, HEPESTaurine12.520.10SupplementB-27™ Supplement1XImage: Component set of the set of t	Lipoic Acid	0.05	2.55E-04		
Putrescine 2HCI0.042.52E-04Other ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04Other ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementB-27™ Supplement (50X), serum free1XImage: Component serueSupplement					
Putrescine 2HCI0.042.52E-04ComponentsDMEM/F-12, HEPESSodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04OtherDMEM/F-12, HEPESTaurine12.520.10SupplementB-27™ Supplement1XImage: Component set of the set	Phenol Red	11.55	0.03		DMEM/F-12, HEPES
Sodium Pyruvate27.500.25Other ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04Other ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementB-27™ Supplement (50X), serum free1XImage: Supplement SupplementSupplement	Dutragaina 2110	0.04		-	
Sodium Pyruvate27.500.25ComponentsDMEM/F-12, HEPESThymidine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementB-27™ Supplement (50X), serum free1XImage: Component serueSupplement		0.04	2.52E-04		
Thymidine0.187.54E-04Other ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementB-27™ Supplement (50X), serum free1XSupplement	Sodium Pyruvate	27 50	0 25		DMEM/E-12 HEPES
Thymidine0.187.54E-04ComponentsDMEM/F-12, HEPESTaurine12.520.10SupplementB-27™ Supplement (50X), serum free1XSupplement		27.00	0.20		
Taurine12.520.10SupplementB-27™ Supplement (50X), serum free1XSupplement	Thymidine	0.18	7.54E-04		DMEM/F-12, HEPES
B-27™ Supplement (50X), serum free 1X Supplement					-
(50X), serum free 1X Supplement		.2.52	0.10		
Fetal Bovine Serum 8% (V/V) Supplement		1X			Supplement
	Fetal Bovine Serum	8% (V/V)			Supplement

Table S7. Medium formulation for mouse retinal explant culture. Related to Figure 2.

Components	Concentration (mg/L)	mM	Category	Source
Glycine	26.25	0.35	Amino Acids	DMEM/F-12, HEPES + NEAA
L-Alanine	13.35	0.15	Amino Acids	DMEM/F-12, HEPES + NEAA
L-Arginine hydrochloride	147.50	0.70	Amino Acids	DMEM/F-12, HEPES
L-Asparagine	19.80	0.15	Amino Acids	DMEM/F-12, HEPES + NEAA
L-Aspartic acid	19.95	0.15	Amino Acids	DMEM/F-12, HEPES + NEAA
L-Cysteine hydrochloride-H2O	17.56	0.10	Amino Acids	DMEM/F-12, HEPES
L-Cystine 2HCI	31.29	0.10	Amino Acids	DMEM/F-12, HEPES
L-Glutamic Acid	22.05	0.15	Amino Acids	DMEM/F-12, HEPES + NEAA
L-Glutamine	365.00	2.50	Amino Acids	DMEM/F-12, HEPES
L-Histidine hydrochloride-H2O	31.48	0.15	Amino Acids	DMEM/F-12, HEPES
L-Isoleucine	54.47	0.42	Amino Acids	DMEM/F-12, HEPES
L-Leucine	59.05	0.45	Amino Acids	DMEM/F-12, HEPES
L-Lysine hydrochloride	91.25	0.50	Amino Acids	DMEM/F-12, HEPES
L-Methionine	17.24	0.12	Amino Acids	DMEM/F-12, HEPES
L-Phenylalanine	35.48	0.22	Amino Acids	DMEM/F-12, HEPES DMEM/F-12, HEPES +
L-Proline	28.75	0.25	Amino Acids	NEAA
L-Serine	36.75	0.35	Amino Acids	DMEM/F-12, HEPES + NEAA
L-Threonine	53.45	0.45	Amino Acids	DMEM/F-12, HEPES
L-Tryptophan	9.02	0.04	Amino Acids	DMEM/F-12, HEPES
L-Tyrosine disodium salt dihydrate	55.79	0.21	Amino Acids	DMEM/F-12, HEPES
L-Valine	52.85	0.45	Amino Acids	DMEM/F-12, HEPES
Biotin	3.50E-03	1.43E-05	Vitamins	DMEM/F-12, HEPES
Choline chloride	8.98	0.06	Vitamins	DMEM/F-12, HEPES
D-Calcium pantothenate	2.24	4.70E-03	Vitamins	DMEM/F-12, HEPES
Folic Acid	2.65	0.01	Vitamins	DMEM/F-12, HEPES
Niacinamide	2.02	0.02	Vitamins	DMEM/F-12, HEPES
Pyridoxine hydrochloride	2.00	0.01	Vitamins	DMEM/F-12, HEPES
Riboflavin	0.22	5.82E-04	Vitamins	DMEM/F-12, HEPES
Thiamine hydrochloride	2.17	0.01	Vitamins	DMEM/F-12, HEPES
Vitamin B12	0.68	5.02E-04	Vitamins	DMEM/F-12, HEPES
i-Inositol	12.60	0.07	Vitamins	DMEM/F-12, HEPES
Calcium Chloride (CaCl2) (anhyd.)	116.60	1.05	Inorganic Salts	DMEM/F-12, HEPES
Cupric sulfate (CuSO4-5H2O)	1.30E-03	5.20E-06	Inorganic Salts	DMEM/F-12, HEPES
Ferric Nitrate (Fe(NO3)3"9H2O)	0.05	1.24E-04	Inorganic Salts	DMEM/F-12, HEPES
Ferrous Sulfate (FeSO4 7H2O)	0.42	1.50E-03	Inorganic Salts	DMEM/F-12, HEPES
Magnesium Chloride	28.64	0.30	Inorganic	DMEM/F-12, HEPES

(anhydrous)			Salts	
Magnesium Sulfate (MgSO4)			Inorganic	
(anhyd.)	48.84	0.41	Salts	DMEM/F-12, HEPES
			Inorganic	
Potassium Chloride (KCI)	311.80	4.16	Salts	DMEM/F-12, HEPES
			Inorganic	
Sodium Bicarbonate (NaHCO3)	1200.00	14.29	Salts	DMEM/F-12, HEPES
	0005 50	400.04	Inorganic	
Sodium Chloride (NaCl)	6995.50	120.61	Salts	DMEM/F-12, HEPES
Sodium Phosphate dibasic	74.00	0.50	Inorganic	
(Na2HPO4) anhydrous	71.02	0.50	Salts	DMEM/F-12, HEPES
Sodium Phosphate monobasic (NaH2PO4-H2O)	62.50	0.45	Inorganic Salts	DMEM/E 12 HEDES
	02.30	0.45		DMEM/F-12, HEPES
Zinc sulfate (ZnSO4-7H2O)	0.43	1.50E-03	Inorganic Salts	DMEM/F-12, HEPES
	0.43	1.502-05	Other	
D-Glucose (Dextrose)	3151.00	17.51	Components	DMEM/F-12, HEPES
	0101.00	17.01	Other	
HEPES	3574.50	15.02	Components	DMEM/F-12, HEPES
			Other	
Hypoxanthine Na	2.39	0.02	Components	DMEM/F-12, HEPES
			Other	
Linoleic Acid	0.04	1.50E-04	Components	DMEM/F-12, HEPES
			Other	
Lipoic Acid	0.11	5.10E-04	Components	DMEM/F-12, HEPES
			Other	
Phenol Red	8.10	0.02	Components	DMEM/F-12, HEPES
			Other	
Putrescine 2HCI	0.08	5.03E-04	Components	DMEM/F-12, HEPES
			Other	
Sodium Pyruvate	55.00	0.50	Components	DMEM/F-12, HEPES
			Other	
Thymidine	0.37	1.51E-03	Components	DMEM/F-12, HEPES
Taurine	12.52	0.10		Supplement
B-27™ Supplement (50X),				
serum free	1X			Supplement
Bovine Serum Albumin solution	1% (V/V)			Supplement

Table S8. Medium formulation for human retinal explant culture. Related to Figure 3.

Components	Concentration (mg/L)	mM	Category	Source
Glycine	26.25	0.35	Amino Acids	Advanced DMEM/F-12 + NEAA
L-Alanine	13.35	0.15	Amino Acids	Advanced DMEM/F-12 + NEAA
L-Arginine hydrochloride	147.50	0.70	Amino Acids	Advanced DMEM/F-12
L-Asparagine-H2O	7.50	0.05	Amino Acids	Advanced DMEM/F-12
L-Asparagine	19.80	0.15	Amino Acids	Advanced DMEM/F-12 + NEAA
L-Aspartic acid	19.95	0.15	Amino Acids	Advanced DMEM/F-12 + NEAA
L-Cysteine hydrochloride- H2O	17.56	0.10	Amino Acids	Advanced DMEM/F-12
L-Cystine 2HCI	31.29	0.10	Amino Acids	Advanced DMEM/F-12
L-Glutamic Acid	22.05	0.15	Amino Acids	Advanced DMEM/F-12 + NEAA
L-Histidine hydrochloride- H2O	31.48	0.15	Amino Acids	Advanced DMEM/F-12
L-Isoleucine	54.47	0.42	Amino Acids	Advanced DMEM/F-12
L-Leucine	59.05	0.45	Amino Acids	Advanced DMEM/F-12
L-Lysine hydrochloride	91.25	0.50	Amino Acids	Advanced DMEM/F-12
L-Methionine	17.24	0.12	Amino Acids	Advanced DMEM/F-12
L-Phenylalanine	35.48	0.22	Amino Acids	Advanced DMEM/F-12
L-Proline	28.75	0.25	Amino Acids	Advanced DMEM/F-12 + NEAA
L-Serine	36.75	0.35	Amino Acids	Advanced DMEM/F-12 + NEAA
L-Threonine	53.45	0.45	Amino Acids	Advanced DMEM/F-12
L-Tryptophan	9.02	0.04	Amino Acids	Advanced DMEM/F-12
L-Tyrosine disodium salt dihydrate	55.79	0.21	Amino Acids	Advanced DMEM/F-12
L-Valine	52.85	0.45	Amino Acids	Advanced DMEM/F-12
Ascorbic Acid phosphate	2.50	0.01	Vitamins	Advanced DMEM/F-12
Biotin	3.50E-03	1.43E-05	Vitamins	Advanced DMEM/F-12
Choline chloride	8.98	0.06	Vitamins	Advanced DMEM/F-12
D-Calcium pantothenate	2.24	4.70E-03	Vitamins	Advanced DMEM/F-12
Folic Acid	2.65	0.01	Vitamins	Advanced DMEM/F-12
Niacinamide	2.02	0.02	Vitamins	Advanced DMEM/F-12
Pyridoxine hydrochloride	2.00	0.01	Vitamins	Advanced DMEM/F-12
Riboflavin	0.22	5.82E-04	Vitamins	Advanced DMEM/F-12
Thiamine hydrochloride	2.17	0.01	Vitamins	Advanced DMEM/F-12
Vitamin B12	0.68	5.02E-04	Vitamins	Advanced DMEM/F-12
i-Inositol	12.60	0.07	Vitamins	Advanced DMEM/F-12
Calcium Chloride (CaCl2) (anhyd.)	116.60	1.05	Inorganic Salts	Advanced DMEM/F-12
Cupric sulfate (CuSO4- 5H2O)	1.30E-03	5.20E-06	Inorganic Salts	Advanced DMEM/F-12
Ferric Nitrate (Fe(NO3)3"9H2O)	0.05	1.24E-04	Inorganic Salts	Advanced DMEM/F-12
Ferric sulfate (FeSO4- 7H2O)	0.42	1.50E-03	Inorganic Salts	Advanced DMEM/F-12
Magnesium Chloride (anhydrous)	28.64	0.30	Inorganic Salts	Advanced DMEM/F-12
Magnesium Sulfate (MgSO4) (anhyd.)	48.84	0.41	Inorganic Salts	Advanced DMEM/F-12
Potassium Chloride (KCI)	311.80	4.16	Inorganic Salts	Advanced DMEM/F-12

Sodium Bicarbonate				
(NaHCO3)	2438.00	29.02	Inorganic Salts	Advanced DMEM/F-12
Sodium Chloride (NaCl)	6995.50	120.61	Inorganic Salts	Advanced DMEM/F-12
Sodium Phosphate dibasic (Na2HPO4) anhydrous	71.02	0.50	Inorganic Salts	Advanced DMEM/F-12
Sodium Phosphate monobasic (NaH2PO4- H2O)	62.50	0.45	Inorganic Salts	Advanced DMEM/F-12
Zinc sulfate (ZnSO4-7H2O)	0.86	3.00E-03	Inorganic Salts	Advanced DMEM/F-12
AlbuMAX® II	400.00	Infinity	Proteins	Advanced DMEM/F-12
Human Transferrin (Holo)	7.50	Infinity	Proteins	Advanced DMEM/F-12
Insulin Recombinant Full	10.00	Infinity	Proteins	Advanced DMEM/F-12
Glutathione, monosodium	1.00	3.26E-03	Reducing Agents	Advanced DMEM/F-12
Ammonium Metavanadate	3.00E-04	2.56E-06	Trace Elements	Advanced DMEM/F-12
Manganous Chloride	5.00E-05	2.53E-07	Trace Elements	Advanced DMEM/F-12
Sodium Selenite	0.01	2.89E-05	Trace Elements	Advanced DMEM/F-12
D-Glucose (Dextrose)	3151.00	17.51	Other Components	Advanced DMEM/F-12
Ethanolamine	1.90	0.02	Other Components	Advanced DMEM/F-12
Hypoxanthine Na	2.39	0.02	Other Components	Advanced DMEM/F-12
Linoleic Acid	0.04	1.50E-04	Other Components	Advanced DMEM/F-12
Lipoic Acid	0.11	5.10E-04	Other Components	Advanced DMEM/F-12
Phenol Red	8.10	0.02	Other Components	Advanced DMEM/F-12
Putrescine 2HCI	0.08	5.03E-04	Other Components	Advanced DMEM/F-12
Sodium Pyruvate	110.00	1.00	Other Components	Advanced DMEM/F-12
Thymidine	0.37	1.51E-03	Other Components	Advanced DMEM/F-12
Taurine	12.52	0.10		Supplement
B-27™ Supplement (50X), serum free	1X			Supplement
Bovine Serum Albumin solution	1% (V/V)			Supplement
CTS™ (Cell Therapy Systems) N-2 Supplement	1X			Supplement
L-Glutamine	292.28	2.00		Supplement

Table S15. Key reagent and resources. Related to Figure 1-4, and Transparent Methods.

Reagent or Media Components	Source	Identifier
DMEM, high glucose, GlutaMAX™ Supplement ^[1]	Thermo Fisher	10566016
DMEM/F-12, HEPES ^{[1], [2]}	Thermo Fisher	11330032
B-27™ Supplement (50X), serum free [1], [2], [3]	Thermo Fisher	17504044
MEM Non-Essential Amino Acids Solution (100X) (NEAA) ^{[1], [2], [3], [4]}	Thermo Fisher	11140050
Fetal Bovine Serum ^{[1], [3], [4]}	Atlanta Biologicals	S11550
GlutaMAX™ Supplement ^[1]	Thermo Fisher	35050061
Bovine Serum Albumin solution ^[2]	Sigma-Aldrich	A1595-50ML
Taurine ^{[2], [3], [4]}		T0625-10G
	Sigma-Aldrich	
Advanced DMEM/F-12 [3]	Thermo Fisher	12634010
CTS™ (Cell Therapy Systems) N-2 Supplement ^[3]	Thermo Fisher	A1370701
L-Glutamine ^[3]	Thermo Fisher	25030081
Minimum Essential Medium Eagle (MEM alpha) ^[4]	Sigma-Aldrich	M4526
N1 Medium Supplement (100×) ^[4]	Sigma-Aldrich	N6530-5ML
Hydrocortisone ^[4]	Sigma-Aldrich	H0888-1G
3, 3', 5-Triiodo-L-Thyronine ^[4]	Sigma-Aldrich	T6397-100MG
HBSS, no calcium, no magnesium	Thermo Fisher	14170112
Corning® Transwell® polyester membrane cell culture inserts	Sigma-Aldrich	CLS3470
CO ₂ Independent Medium	Thermo Fisher	18045088
Neurobasal™-A Medium	Thermo Fisher	10888022
Biopsy Punch	Kai Medical	BP-50F, 5.0 mm
Corning® Transwell® polycarbonate membrane cell culture inserts	Sigma-Aldrich	CLS3421
Mass Spectrometry (GC MS)	Olgina-Aldrich	0200421
Water, Optima™ LC/MS Grade	Fisher Chemical	166415
Methanol	Fisher Chemical	164905
Methoxyamine hydrochloride	Sigma-Aldrich	226904
Pyridine	Sigma-Aldrich	270970
N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide	Sigma-Aldrich	394882
DB-5ms GC Column, 30 m, 0.25 mm, 0.25 um	Agilent	1225532
Cal Duran	Technologies	00140
Gel Pump Speed vac Plus	Savant Savant	GP110 SC110A
Centrifuge	Eppendorf	5424
Acquity UPLC BEH Amide 1.7 µm Vanguard pre-column 2.1 x 5mm	Waters	186004799
column	Waters	100004799
Acquity UPLC BEH Amide 1.7 µm 2.1 x 50mm column	Waters	186004800
Acetonitrile, Optima™ LC/MS Grade	Fisher Chemical	75-05-8
Ammonium Acetate	Sigma-Aldrich	431311
Ammonium hydroxide 28 - 30% in water ACS	VŴR	AC42330-5000
Animals		
C57BL/6J	Jackson Lab	000664
Nrl knockout mice	Anand Swaroop Lab	

[1] Retinal organoid culture medium[2] Mouse retinal explant culture medium[3] Human retinal explant culture medium[4] Human RPE explant culture medium

Table S16. The medium formulation for human RPE/choroid culture. Related to Figure 4.

Components	Concentration (mg/L)	mМ	Category	Source
Glycine	57.5	0.77	Amino Acids	MEM alpha + NEAA
L-Alanine	33.9	0.38	Amino Acids	MEM alpha + NEAA
L-Arginine hydrochloride	105.0	0.50	Amino Acids	MEM alpha
L-Asparagine-H2O	63.2	0.43	Amino Acids	MEM alpha + NEAA
L-Aspartic acid	43.3	0.33	Amino Acids	MEM alpha + NEAA
L-Cysteine hydrochloride- H2O	100.0	0.57	Amino Acids	MEM alpha
L-Cystine 2HCI	31.0	0.10	Amino Acids	MEM alpha
L-Glutamic Acid	89.8	0.61	Amino Acids	MEM alpha + NEAA
L-Glutamine	292.0	2.00	Amino Acids	MEM alpha
L-Histidine hydrochloride- H2O	42.0	0.20	Amino Acids	MEM alpha
L-Isoleucine	52.4	0.40	Amino Acids	MEM alpha
L-Leucine	52.0	0.40	Amino Acids	MEM alpha
L-Lysine hydrochloride	73.0	0.40	Amino Acids	MEM alpha
L-Methionine	15.0	0.10	Amino Acids	MEM alpha
L-Phenylalanine	32.0	0.19	Amino Acids	MEM alpha
L-Proline	51.5	0.45	Amino Acids	MEM alpha + NEAA
L-Serine	35.5	0.34	Amino Acids	MEM alpha + NEAA
L-Threonine	48.0	0.40	Amino Acids	MEM alpha
L-Tryptophan	10.0	0.05	Amino Acids	MEM alpha
L-Tyrosine disodium salt	52.0	0.20	Amino Acids	MEM alpha
L-Valine	46.0	0.39	Amino Acids	MEM alpha
Ascorbic Acid	50.0	0.28	Vitamins	MEM alpha
Biotin	1.0E-01	4.00E-04	Vitamins	MEM alpha
Choline chloride	1.0	7.10E-03	Vitamins	MEM alpha
D-Calcium pantothenate	1.0	2.10E-03	Vitamins	MEM alpha
Folic Acid	1.0	2.30E-03	Vitamins	MEM alpha
Niacinamide	1.0	8.20E-03	Vitamins	MEM alpha
Pyridoxal hydrochloride	1.0	4.90E-03	Vitamins	MEM alpha
Riboflavin	1.0E-01	3.00E-04	Vitamins	MEM alpha
Thiamine hydrochloride	1.0	3.00E-03	Vitamins	MEM alpha
Vitamin B12	1.4	1.00E-03	Vitamins	MEM alpha
i-Inositol	2.0	1.11E-02	Vitamins	MEM alpha
Calcium Chloride (CaCl2) (anhyd.)	200.0	1.80	Inorganic Salts	MEM alpha

Magnesium Sulfate (MgSO4) (anhyd.)	97.7	0.81	Inorganic Salts	MEM alpha
Potassium Chloride (KCI)	400.0	5.33	Inorganic Salts	MEM alpha
Sodium Bicarbonate (NaHCO3)	2200.0	26.19	Inorganic Salts	MEM alpha
Sodium Chloride (NaCl)	6800.0	117.24	Inorganic Salts	MEM alpha
Sodium Phosphate monobasic (NaH2PO4-H2O)	140.0	1.01	Inorganic Salts	MEM alpha
D-Glucose (Dextrose)	1000.0	5.56	Other components	MEM alpha
Lipoic Acid	0.2	1.00E-03	Other components	MEM alpha
Phenol Red	10.0	0.03	Other components	MEM alpha
Sodium Pyruvate	110.0	1.00	Other components	MEM alpha
Recombinant human insulin	5.0		Other components	N1 Supplement
human transferrin	5.0		Other components	N1 Supplement
Sodium selenite	5.0E-03		Other components	N1 Supplement
Putrescine	16.0		Other components	N1 Supplement
Progesterone	7.3E-03		Other components	N1 Supplement
Taurine	250.0			Supplement
Hydrocortisone	2.0E-02			Supplement
triiodo-thyronine	1.3E-05			Supplement
Fetal Bovine Serum	1% (V/V)			Supplement

Transparent Methods

Reagents

All the reagents and resources are detailed in the Key Resources table (Table S15)

Human retinal organoid culture

Cone-rich human retinal organoids were generated from H1 human embryonic stem cells (WiCell) using a method described previously (Kim et al., 2019; Lowe et al., 2016). For the assay of metabolite consumption, one retinal organoid on day 56 or day 296 was grown in a well of a 24-well plate containing 800 µl of culture medium (DMEM/F12 (3:1), 2% B27, 1x non-essential amino acids (NEAA), 8% fetal bovine serum (FBS), 100 µM Taurine and 2 mM GlutaMAX (see detail information in **Table S6** and **Table S15**). Culture wells containing 800 µl of the medium without retinal organoids were used as baseline controls. After 48 hours of culture, 50 µl of the spent medium was collected from each culture well for metabolite analysis.

Mouse retinal explant culture

Nrl KO mice were generously provided by Anand Swaroop, PhD (National Eye Institute, Bethesda, MD) and were housed and bred at the West Virginia University Animal Research Facility vivarium. The *Nrl* KO mice were bred with C57BL6/J mice purchased from Jackson Laboratories (Bar Harbor, ME) to generate *Nrl* Het mice which were further bred with *Nrl* KO mice. Our studies used littermates at postnatal 36 days with half male and half female. All procedures were in accordance with the National Institutes of Health guidelines and the protocols approved by the Institutional Animal Care and Use Committee of West Virginia University. Mouse explant culture was performed as previously reported (Chao et al., 2017). Briefly, the retina was isolated and made four relief cuts on each side in retinal culture medium containing DMEM/F12 (3:1), 2% B27, 1x NEAA, 1% FBS, and 100 µM Taurine (detailed in **Table S7** and **Table S15**). The retina was then transferred into an insert of 24-well transwell plate with photoreceptor-side facing down. The bottom chamber contained 500 µl and top chamber 100 µl of retinal culture medium. Transwells containing medium without retinas were cultured as the baseline controls. After 24 hours, 50 µl of the spent medium was collected from the bottom chamber for metabolite analysis.

Human retina and RPE/choroid explant culture

Post-mortem donor eyes without known eye conditions were obtained from Lions NSW eye bank. Ethical approval for this project was obtained from the Human Research Ethics Committee of the University of Sydney. The eyes were kept in CO₂ independent medium in 4°C until further dissection. All donor eves within 28 hours post-mortem (Table S5) were cut open by removing iris and lens, followed by cutting a circle of the sclera with 0.5cm thickness. Fundus photographs were taken by a digital microscope camera (Jenoptik Optical System) after the anterior segment was removed. The whole neural retina was gently detached after separated from the ora serrata and optic nerve head. Then it was bluntly separated from vitreous and the neural retina was unfolded in a glass petri dish (150mm×15mm) with neurobasal-A medium. 5mmdiameter circular neural retinas were trephined from the macula and superior mid-peripheral retina using a Biopsy Punch (Figure 3A). The macula punch was on the fovea. Mid-periphery was defined as the mid-point between the macula lutea and the ora serrata. RPE-choroid-sclera complexes (RPE/choroid) were trephined from macula and mid-periphery as the same location in retinal punches. Both retinal and RPE/choroid explants were transferred to the inserts of 24-well transwell plates (Corning, CLS3421) with culture medium. Neural explants were cultured with photoreceptors facing down, and RPE-choroid-sclera complexes were cultured with RPE layer facing up to protect the photoreceptor outer segment and RPE from physical damage (Murali et al., 2019). Retinal culture media was modified from mouse retinal culture (Table S8 lists detail formulation) and RPE/choroid culture media was the same as we reported (Chao et al., 2017) (Table S16). The volume of medium for neural explants in the insert is 100µl and in well is 600µl. The volume for RPE explant is 150µl in insert and 900µl in well. Table 15 listed details for the supplies and culture media. Neural retina and RPE explants were cultured for 24h at 37°C in 5% CO₂ incubator. There was space around tissue explants and the nutrients can readily exchange between upper chamber and lower chamber. To avoid potential tissue debris in the upper chamber, we collected 10µl spent medium from the lower chamber for metabolite analysis.

Metabolite analysis

Metabolites were extracted from 10 μ I of medium samples, dried with freeze dryer, and analyzed with Liquid chromatography-mass spectrometry (LC MS) and gas chromatography-mass spectrometry (GC MS) as described (Chao et al., 2017; Grenell et al., 2019; Yam et al., 2019). LC MS used a Shimadzu LC Nexera X2 UHPLC coupled with a QTRAP 5500 LC MS (AB Sciex). An ACQUITY UPLC BEH Amide analytic column (2.1 X 50 mm, 1.7 μ m, Waters) was used for chromatographic separation. A total of 190 metabolites were measured with optimal parameters for targeted metabolomics (**Table S1**). GC MS used an Agilent 7890B/5977B system with a DB5MS column (30 m × 0.25 mm × 0.25

 μ m). Mass spectra were collected from 80–600 m/z under selective ion monitoring mode to quantify 28 metabolites (**Table S1**). The ion abundance of each metabolite was divided by those from baseline controls to obtain fold changes in abundance. Metabolite uptake was defined as the significantly changed metabolites with fold changes <-1, and metabolite release was defined as the significantly changed metabolites with fold changes >1.

Statistics

The significance of differences between means was determined by unpaired or paired two-tailed t tests using GraphPad Prism 7. The data were presented as mean \pm Standard error of mean (SEM). P < 0.05 was considered to be significant. The differences in metabolic genes were analyzed by Volcano plot using MetaboAnalyst 4.0 (https://www.metaboanalyst.ca/). The changes with fold changes >1.3 and P<0.05 were set as significant.

Supplemental Refereences

Chao, J.R., Knight, K., Engel, A.L., Jankowski, C., Wang, Y., Manson, M.A., Gu, H., Djukovic, D., Raftery, D., Hurley, J.B., *et al.* (2017). Human retinal pigment epithelial cells prefer proline as a nutrient and transport metabolic intermediates to the retinal side. The Journal of biological chemistry 292, 12895-12905.

Grenell, A., Wang, Y., Yam, M., Swarup, A., Dilan, T.L., Hauer, A., Linton, J.D., Philp, N.J., Gregor, E., Zhu, S., *et al.* (2019). Loss of MPC1 reprograms retinal metabolism to impair visual function. Proceedings of the National Academy of Sciences of the United States of America *116*, 3530-3535.

Kim, S., Lowe, A., Dharmat, R., Lee, S., Owen, L.A., Wang, J., Shakoor, A., Li, Y., Morgan, D.J., Hejazi, A.A., *et al.* (2019). Generation, transcriptome profiling, and functional validation of cone-rich human retinal organoids. Proceedings of the National Academy of Sciences of the United States of America *116*, 10824-10833.

Lowe, A., Harris, R., Bhansali, P., Cvekl, A., and Liu, W. (2016). Intercellular Adhesion-Dependent Cell Survival and ROCK-Regulated Actomyosin-Driven Forces Mediate Self-Formation of a Retinal Organoid. Stem cell reports *6*, 743-756.

Murali, A., Ramlogan-Steel, C.A., Andrzejewski, S., Steel, J.C., and Layton, C.J. (2019). Retinal explant culture: A platform to investigate human neuro-retina. Clinical & experimental ophthalmology *47*, 274-285.

Yam, M., Engel, A.L., Wang, Y., Zhu, S., Hauer, A., Zhang, R., Lohner, D., Huang, J., Dinterman, M., Zhao, C., *et al.* (2019). Proline mediates metabolic communication between retinal pigment epithelial cells and the retina. The Journal of biological chemistry.